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Boron neutron capture therapy (BNCT) for the treatment of prostate cancer using a 
boron-containing cholesteryl ester compound (BCH) was investigated.  BNCT is a binary 
radiation therapy that relies on targeted delivery of 
10
B to cancer cells followed by 
irradiation with thermal neutrons.  High-linear energy transfer (LET)  particles and 
7
Li 
nuclei released from the 
10
B neutron capture event result in lethal double-strand DNA 
breaks within a 9 m range.  Given the high density energy deposition and short range, 
neighboring cells without 
10
B remain unharmed.  To evaluate the efficacy of BCH as a 
BNCT compound, a sample chamber within the thermal column experimental facility of 
the Maryland University Training Reactor (MUTR) was designed to provide a means of 
irradiating samples in vitro in a thermal neutron field.  The thermal neutron fluence rate 




/s with the < 3 eV neutron 
energy region representing 94.6% of the total neutron field.  The hydrophobic BCH 
  
compound was embedded in the lipid bilayer of DPPC:cholesterol liposomes for delivery 
to PC-3 prostate cancer cells.  Liposomes were synthesized by the thin film layer 
technique with high-pressure homogenization size reduction.  Dynamic light scattering 
analysis of the liposomes yielded a mean diameter of 111.5 nm and 0.113 relative 
variance.  Cytotoxicity of the BCH-containing liposomes was evaluated by neutral red, 
MTS, LDH, and colony formation assays.  Boron uptake by PC-3 cells was analyzed with 
high-performance liquid chromatography (HPLC) and inductively coupled plasma-mass 
spectrometry (ICP-MS).  Drug delivery conditions that minimized cytotoxic effects 
yielded a boron uptake of 35.2 + 4.3 g/g cell.  PC-3 cells were irradiated in the MUTR 
thermal column sample chamber to quantify the enhanced cell killing of the high-LET 
thermal neutron capture 
10





/s thermal neutron fluence yielded a 20-25% increase in cell death compared 
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Chapter 1: Introduction 
 
According to the American Cancer Society, prostate cancer is the most frequently 
diagnosed cancer and the second leading cause of cancer death in men.  It is estimated 
that 238,590 new cases of prostate cancer will occur in the United States this year (2013), 
with 29,720 cases resulting in death.[1]  Because of this, the development of new 
treatment options involving targeted drug delivery to improve the efficacy of prostate 
cancer treatment is essential.  
 
The goal of targeted drug therapy is to selectively deliver anti-cancer drugs to cancer 
cells, resulting in fewer side effects for the patient.  One of the fundamental approaches is 
to design novel anti-cancer compounds that capitalize on the biological differences 
between cancer and normal cells.  It has been reported that prostate cancer cells, like 
many other types of cancer cells, have high expression of low-density lipoprotein (LDL) 
receptors and lack feedback regulation of LDL receptor expression in order to accelerate 
their characteristic abnormal growth.[2]  Therefore, targeted drug delivery can be 
accomplished by synthesizing cholesterol-based anti-cancer compounds specific to these 
LDL receptors.  With this in mind, a new anti-cancer cholesteryl carborane ester 
compound (BCH) was synthesized for testing.[3]  This compound was designed to mimic 
the native cholesteryl esters in the human body, and thus follow the same pathway to be 
selectively taken up by cancer cells via the elevated expression of LDL receptors within 






This research evaluates the efficacy of thermal neutron irradiation of prostate cancer cells 
containing the carborane compound, BCH, for the treatment of prostate cancer.  The 
BCH compound has the potential to selectively target prostate cancer cells for boron 
neutron capture therapy (BNCT).  Specifically, the development of a drug delivery 
method for preferential BCH-loading in prostate cancer cells, quantitative analysis of 
BCH uptake, cytotoxicity of boron-containing liposomes, and in vitro cell survival of 
BCH-containing cells following high-LET  particle and 
7
Li release from 
10
B thermal 
neutron capture have been investigated. 
 
1.1  Global Objective 
 
 
The global objective of this research is to investigate the efficacy of a novel boron-
containing cholesteryl ester compound, BCH, as a targeting compound for BNCT of 
prostate cancer.  To accomplish this goal, a thermal neutron irradiation facility at the 
University of Maryland was designed, fabricated, and characterized to provide a proper 
experimental facility to expose the boron-containing prostate cancer cells to a 
thermalized neutron beam with minimal high energy neutron beam contamination and -
ray dose contribution.  The global hypothesis of this dissertation is that by utilizing a 
targeted delivery pathway specific to prostate cancer cells, the boron-containing cells 
treated with the BNCT agent will exhibit lower cell survival following irradiation with a 
thermal neutron beam compared to the control cells that did not receive treatment with 








1.1.1  Specific Hypotheses and Aims 
 
1.  The Maryland University Training Reactor (MUTR) is capable of providing a thermal 
neutron beam for the purpose of evaluating the efficacy of BNCT in biological samples. 
 
 Design and fabricate a thermal column access plug for the irradiation of biological 
samples within the nuclear reactor thermal column. 
 Characterize the neutron and -ray radiation fields within the thermal column 
access plug utilizing ionization chambers, foil activation, and computer modeling. 
 
2.  Encapsulation of BCH into the lipid bilayer of liposomes is an effective means of 
delivering the cholesteryl ester compound to prostate cancer cells. 
 
 Quantify the loading efficiency of BCH encapsulation in liposomes following 
synthesis and size reduction. 
 Analyze the size distribution of BCH-containing liposomes with dynamic light 
scattering. 
 Measure the cytotoxic effects of the BCH-containing liposomes on the prostate 
cancer cells. 
 Determine the delivery parameters required to attain sufficient boron loading 





performance liquid chromatography (HPLC) and inductively coupled plasma-
mass spectrometry (ICP-MS). 
 
3.  The targeted delivery of BCH to prostate cancer cells decreases cell survival following 
irradiation in a thermal neutron beam due to the generation of high-LET  particles and 
7
Li nuclei from 
10
B capture reactions. 
 
 Compare the cell survival of prostate cancer cells with and without BCH after 







Chapter 2: Technical Background 
 
2.1  Physics of Boron Neutron Capture Therapy 
 
Boron neutron capture therapy (BNCT) is a binary radiation cancer treatment with 
potentially significant therapeutic advantages compared to conventional chemical and 
radiation therapies.  The treatment is based on specific cell killing by neutron irradiation 
of cancer cells that have been preferentially loaded with a boron-containing compound.  
The nuclear reaction between a thermal neutron and a 
10
B atom produces a high-linear 









Li (0.84 MeV) + 
4






Li (1.01 MeV) + 
4
He (1.78 MeV)   6% (2-2) 
 
These high-LET particles impart their energies in a relatively short range, approximately 
9 and 5 m respectively.[5]  Because this distance is on the same scale as a typical cell 
diameter, the particles are theoretically capable of fatally damaging cells containing the 
10
B, while leaving neighboring cells unharmed.[6-8]  The 1.5 MeV  particles that result 
from this capture reaction have an average LET of ~200 keV/m, therefore capable of 
imparting lethal damage when only a few particles deposit their energy.[9]  Figure 2-1 







Figure 2-1.  BNCT cell killing mechanism from 
10
B capture of a thermal neutron 
resulting in the release of a high-LET particle and 
7
Li nuclei.   
 
It is important to note that hydrogen and nitrogen found within normal tissue can also 
participate in capture reactions to produce -rays and protons.  However, the thermal 
neutron cross sections of these atoms are very small in comparison to 
10
B, as shown in 
Table 2-1, and do not contribute significantly to the thermal neutron capture dose 











Table 2-1.  Cross sections for relevant BNCT nuclear reactions. 















There are several advantages of BNCT for targeted treatment:  (1) because the boron-
containing compounds are neither required to be cytotoxic nor to release anti-cancer units 
in the cells, boron conjugates can be designed solely for targeted delivery purposes, (2) 
radiation can be applied in a time window (radiation window) when the therapeutic ratio 
of boron-containing compounds in the cancer cells versus the surrounding normal tissue 
reaches a maximum, and (3) BNCT is particularly suitable for prostate cancer treatment 
because the physiological location of the prostate is distant from many vital organs and 
can thus be targeted with a direct neutron beam.[5, 7, 10]   
 
The biological effects of radiation damage are principally observed as damage to DNA.  
This damage can be the result of either direct or indirect action of radiation.  In direct 
action, radiation interacts with the target DNA molecule causing ionization or excitation.  
While direct action can be initiated by any form of radiation (x-rays, -rays, charged and 
uncharged particles), it is most often the result of radiation with high-LET.  LET is the 
amount of energy that is transferred to a material per unit length of the radiation track, 





in size and carry a charge (i.e. particles) are known as densely ionizing, while low-LET 
radiation (i.e. x-rays) is referred to as sparsely ionizing.  Indirect action, on the other 
hand, occurs as radiation is absorbed by matter (typically water) surrounding the target 
DNA molecule, leading to the formation of free radicals.  These free radicals then diffuse 
to the DNA and interact with the target molecule.  Further discussion of radiation induced 
DNA damage is provided in Chapter 7. 
 
2.2  BNCT Clinical Trials 
 
The first clinical trials for BNCT of glioblastoma multiforme (GBM) with borax and 
sodium pentaborate as the boron agents were initiated in the 1950s at the Brookhaven 
National Laboratory (BNL) and the Massachusetts Institute of Technology Reactor 
(MITR), however they were terminated in 1961 when it was determined that the 
treatments were not as effective as anticipated.[11, 12]  Analysis of the data showed that 
biodistribution studies and improved characterization of radiation sources were key 
factors that needed to be addressed for the future success of BNCT as a potential large-
scale treatment option.[13]  Studies began again in Japan in 1967 using BSH as the 
boron-containing agent in combination with tumor “debulking”.  Thermal neutron beams 
were utilized with craniotomies to increase neutron penetration and limit exposure to the 
skin.[14, 15]  While failing to provide an increase in patient survival times, the results 
were promising when compared to previous reports.  Clinical use of BPA to treat patients 
with cutaneous malignant melanomas began in the late 1980s.[16]  Reported successes in 





of GBM in 1994.[17]  A key difference in these trials was the use of epithermal neutron 
beams to provide deeper tissue penetration, thus avoiding opening of the skull as 
previously performed in the Japanese trials.  Other advantages included the development 
of Monte Carlo treatment planning, improved physical dosimetry, and reliable boron 
analysis techniques.[18]  The trials at BNL and MITR produced results comparable to 
conventional photon therapies.[19]  Trials from Sweden and Finland have shown 
considerable increases in survival times compared to trials in the USA, although direct 
comparisons are difficult due to variations in therapy planning.  Other clinical trials for 
BNCT treatment of melanomas, head and neck tumors, and colon adenocarcinoma have 
taken place in the US, Japan, Germany, Finland, Czech Republic, Argentina, Sweden, 
and Taiwan.  A complete review of these trials is beyond the scope of this dissertation 
and can be found elsewhere.[6, 18, 20] 
 
2.2  Drug Design and Synthesis 
 
The overall success of BNCT is contingent on the ability to synthesize boron-containing 
compounds that satisfy the following requirements:  (1) selective targeting of cancer 




B atoms/cell ( ~20 
g/g tumor), (3) minimum tumor-to-normal tissue differential in the 3-5 range, (4) 
persistent cellular concentration of 
10
B throughout the irradiation procedure, and (5) low 






Currently, three boron-containing compounds are approved for clinical trials by the US 
Food and Drug Administration (FDA) with Investigational New Drug classification.  The 
first, borocaptate sodium Na2[closo-B12H11SH] (BSH), is a carborane derivative 
containing ten boron atoms per molecule that has been used in BNCT treatment of GBM, 
and its biodistribution in animals has been studied.[24-28]  The second, 4-
dihydroxyborylphenyl-alanine (BPA), is an amino acid containing one boron atom per 
molecule that has been used to treat patients suffering from malignant melanoma and 
GBM, with similar studies in animal biodistribution.[29-33]  The third, polyhedral borane 
dianion [closo-B10H10]
2-
 (GB-10), has been studied for its ability to treat GBM.[34, 35]  
Each of these compounds is shown in Figure 2-2. 
 
 
Figure 2-2.  FDA approved BNCT agents. 
 
However, each of these compounds has limitations in selective tumor targeting and 
retention, leading to interest in the development of new compounds with the ability to 
better satisfy the criteria previously described.  The goal of developing and evaluating 
more selective boron delivery agents has been deemed the single greatest need for the 
future progress and success of BNCT.[36]  A more complete discussion of these 
compounds can be found elsewhere.[5, 37]  In addition to these FDA approved drugs, 





limited to:  boronated porphyrins, boronated nucleosides and nucleotides, monoclonal 
antibodies, and growth factors.[5, 7]  
 
A promising new cholesteryl carborane ester compound (BCH) was synthesized that 
mimics the structure of native cholesteryl ester and contains a carborane cage as the 
source of boron for BNCT.[4, 38]  This compound was evaluated in this research project 
for targeted therapy of prostate cancer.  The structure of BCH is shown in Figure 2-3. 
 
 
Figure 2-3.  Chemical structure of BCH. 
 
Similar to BSH, a boron cage is attached to the end of the molecule which contains ten 
boron atoms.  In addition to this, the para-carborane cage increases the lipophilicity of 
the molecule, which may improve incorporation of the molecule into low-density 
lipoproteins (LDL).[39-41]  Due to the high hydrophobicity of the BCH molecule, 
incorporation in a liposome formulation is required for delivery into a biological 
system.[4]  Studies involving BCH uptake of normal neuron cells and brain glioma tumor 







2.3  Targeted Drug Delivery 
 
The success of BNCT rests in the ability to specifically target cancer cells for delivery of 
boron while limiting the uptake by normal cells.  Methods to address this issue include 
synthesis of individually targeting boron-containing compounds, conjugation of boron-
containing compounds to macromolecules, and encapsulation of the compounds in 




Figure 2-4.  Methods of BNCT agent delivery. 
Another method for targeted delivery of 
10
B to cancer cells is based on the over-





46]  Specifically, it has been reported that human prostate cancer cells (PC-3) lack the 
feedback regulation of LDL receptors seen in normal human prostate cells.[2]  LDL is a 
20-25 nm particle consisting of a lipid monolayer containing apolipoprotein that binds to 
LDL receptors, surrounding approximately 1,500 cholesteryl esters within its 
hydrophobic core.  LDL is the primary carrier of cholesterol in the blood stream and 
accounts for up to 90% of cholesterol found in the cell, the balance resulting from de 
novo synthesis.[47]   
 
 
Figure 2-5.  The structure of low-density lipoprotein (LDL). 
 
LDL receptors are more active in many rapidly dividing cancer cells, likely due to the 
formation of new cell membranes which require high levels of cholesterol.[48, 49]  The 
pathway for cellular uptake of LDL is termed receptor-mediated endocytosis and relies 
on cellular synthesis of transmembrane LDL receptors that are expressed on the cell 





the lysosomes, where the LDL particles are hydrolyzed to form free cholesterol that can 
be used by the cells.   
 
Figure 2-6.  Mechanism of receptor-mediated endocytosis whereby LDL (yellow circles) 
carrying cholesterol and cholesterol esters bound to LDL receptors (light blue Y-shape) is 
internalized and transported to sorting endosomes and to late endosomes and 
lysosomes.[50] 
 
In normally functioning cells, feedback regulation prevents expression of LDL receptors 
on the cell surface once a sufficient amount of cholesterol has been accumulated.  In 
certain cancer cells however, this feedback is not present and cells will continue to 
endcytose LDL.  Therefore, successfully incorporating BCH into LDL provides a means 







In order to introduce BCH into the LDL, the hydrophobic compound must be 
incorporated into liposomes.  The liposomes contain a mixture of 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC), cholesterol, and BCH.  As described in Chapter 5, the 
compounds are mixed and dried to form a thin film which is then hydrated and agitated to 
form the liposome formulation.  Following homogenization, the liposomes mix with LDL 
in the cell media.  The liposomes provide a means of solubilizing the BCH and facilitate 
interaction with the LDL.  Liposomes are able to interact with LDL through mechanisms 
of fusion, lipid transfer, and lipid exchange because they are both lipid based particles, 
creating an efficient means of loading hydrophobic drugs into LDL.[40, 42, 51]   
 
2.4  Neutron Irradiation 
 
An area of importance for the success of BNCT is the availability of a neutron source.  
To date, the dominant source of neutrons for BNCT is a fission reactor.  An in depth 
discussion and review of modifications and construction of experimental facilities 
throughout the world for delivery of fission reactor-based neutron beams can be found in 
the following references.[52, 53]   
 
Within the reactor core, neutrons are born from 
235
U fission with energy ranging from 
fast to thermal.  In order to improve the probability of interaction between neutrons and 
boron atoms within the cell, neutrons must be thermalized.  This occurs by interaction 
with a moderator, causing neutrons to lose energy through collisions with other atoms.  





enough energy to penetrate to the tumor depth.  To resolve this problem, clinical sites are 
currently investigating the use of epithermal neutron beams that are moderated as they 
penetrate tissue, becoming thermal upon interaction with the tumor.[54, 55]  Epithermal 
neutron beams have been utilized for BNCT therapy at reactors in the US at BNL and the 
MITR.  In addition to this, reactors in The Netherlands, Finland, Sweden, the Czech 
Republic, and Japan are modifying reactors for research involving BNCT.[6]  However, 
for research in an in vitro setting, the development of thermal neutron beams is of 
significant importance.  Monoenergetic neutron beams from a 
235
U fission source are not 
attainable and will always be contaminated with higher energy neutrons and -rays which 
lead to non-specific cell killing; but by increasing shielding and beam moderation, a 
higher proportion of incident radiation is delivered by thermal neutrons. 
 
The capture of neutrons by 
10
B is highly dependent on the energy of the incident neutron.  
The absorption cross section, which identifies the probability of interaction between a 







Figure 2-7.  Absorption cross sections for 
10




As shown in the plot, the probability of neutron capture is largely dependent on the 
incident neutron energy.  Therefore, it is very important to carefully characterize the 
neutron spectrum to ensure that the BNCT agent delivered to the tumor cells will undergo 
the capture process that results in the cell killing.  The development and characterization 
of a thermal neutron experimental facility is discussed in Chapters 3 and 4. 
 
There is great interest in the development of accelerator-based neutron sources (ABNS) 
for use in hospital settings; however, to date this mechanism of thermal neutron delivery 
is still in its infancy.  In general, the achievable neutron fluence rates from ABNS 
compared to fission reactor sources are insufficient to provide the desired neutron fluence 
within a reasonable amount of time.[18]  Development of this type of neutron source 





elsewhere.[6, 7, 56-58]  The first ABNS for clinical use is currently being developed in 






Chapter 3: Nuclear Reactor Facility Development 
 
3.1  Maryland University Training Reactor Facility  
 
The 250 kW TRIGA Maryland University Training Reactor (MUTR) provides an ideal 
source of thermal neutrons for BNCT.  The core of the MUTR presents a rectangular 
array of fuel elements consisting of UZrH fuel enriched to < 20% and three borated 
carbide control rods housed in a 6,000 gallon light water pool.  The MUTR core is shown 
in Figure 3-1. 
 
 
Figure 3-1.  Overhead view of the 250 kW TRIGA MUTR core. 
 
The fuel used in the MUTR core is referred to as Training, Research, Isotope production 
General Atomic (TRIGA) fuel due to its original design as a radiation source for research 





document GA-471 “Technical Foundations of TRIGA.”[59]  Briefly, TRIGA fuel 
elements contain a mixed UZrH fuel-moderator surrounding a zirconium rod and clad in 
304-stainless steel.  Mixing the hydrogen moderator with the fuel allows for 
approximately 80% of the neutron moderation to occur within the fuel elements.  The 
remaining 20% of neutron moderation occurs in the light water surrounding the MUTR 
core.  The zirconium rod provides stability for the fuel element while minimizing neutron 
capture within the structural material.  The stainless steel cladding provides safe 
encapsulation of fission products while allowing sufficient heat transfer from the fuel to 
the light water coolant and minimizing neutron absorption in non-fuel material.  Graphite 
reflectors are positioned at the top and bottom of the fuel section to minimize neutron 








Figure 3-2.  Schematic of a TRIGA fuel element. 
 
To initiate the fission process, control rods are withdrawn from the core to increase the 
probabilty of neutron interaction with the 
235
U within the fuel.  A plutonium-beryllium 
neutron startup source provides the initial neutrons for the chain reaction.  Neutrons are 
emitted from the startup source and travel through the light water moderator until they are 
captured by a 
235
U atom.  Once captured, 
235
U undergoes fission whereby fission 







Figure 3-3.  Thermal neutron capture of 
235
U resulting in a fission event releasing 2-3 
neutrons and fission fragments. 
 
 
Of particular interest are the fission neutrons released from this reaction.  Neutrons born 
immediately from the fission event are referred to as prompt neutrons and represent 
99.3% of all fission neutrons.  The remaining 0.7% are referred to as delayed neutrons 
and are emitted at a later time following the decay of fission fragments, known as delayed 
neutron precursors.  It is important to note that neutrons born from fission have a skewed 
Gassian energy distribution with an average energy of 1-2 MeV.  There are higher energy 
neutrons emitted (on the scale of 10 MeV), however, as shown in Figure 3-4 the 







Figure 3-4.  
235
U fission neutron energy spectrum. 
 
Once born from fission, neutrons begin the process of moderation (also referred to as 
thermalization).  As the neutrons pass through the hydrogenous material within the fuel 
matrix and light water surrounding the core, energy is transferred through collisions with 
similar Z (atomic number) matter and the epithermal and thermal energy regions are 
approached.  Neutron moderation is critical because of the energy-dependent relationship 
between cross section and incident neutron.  A representative cross section graph is 






Figure 3-5.  A representative neutron cross section as a function of energy identifying the 
thermal, epithermal, and fast regions. 
 
The probability of neutron interaction increases proportional to 1/v in the thermal region.  
Because of this, a majority of 
235
U fission events within the reactor core are a result of 
thermal neutron capture.  Without adequate moderation to transition the higher energy 
neutrons born from a fission event to the lower energy regions, a chain reaction could not 
be sustained.  Further discussion of neutron behavior as a function of energy and the 
importance of neutron moderation is found in Chapter 4. 
 
While scattering within the fuel elements and light water moderator shift the neutron 
spectrum to a lower energy, further neutron beam moderation is required to produce a 
thermal neutron beam for BNCT.  A schematic of the experimental facilities at the 







Figure 3-6.  Schematic of the MUTR core and surrounding experimental facilities. 
 
The thermal column [60] experimental facility was utilized for the in vitro BNCT 
irradiations.  The TC is a graphite-filled housing extending from the southern face of the 
core through the pool tank wall and the concrete shield.  The core end of the housing 
consists of a 0.953 cm (0.375 in.) thick aluminum sleeve that passes through an aluminum 
nozzle welded to the pool tank wall.  The liner extends through the concrete shield and 





) graphite stringers arranged to form a stepped column 1.52 m (59.8 in.) 
in length.  The section forward of the step is 0.959 m (37.8 in.) long and 0.610 m (24.0 in.) 
wide, in which the stringers are arranged in a 6 x 6 pattern.  The outer section of the 
graphite column is 0.565 m (22.2 in.) long and 0.813 m (32.0 in.) wide with stringers 
arranged in an 8 x 8 pattern surrounded with 0.318 cm (0.125 in.) thick boral.  Lead bricks 







Figure 3-7.  MUTR thermal column experimental facility. 
 
 
3.2  Thermal Column Design and Fabrication 
 
The original TC access plug was removed for the first time since the reactor was fueled 
with its current TRIGA rods in 1974 and replaced with a new setup which allows samples 
to be irradiated in the TC while controlling and monitoring the environmental conditions 
within the sample chamber.  The goal was to provide a sample chamber where the 
surrounding gaseous atmosphere and temperature could be controlled throughout an 
irradiation and customized to the specific needs of the sample conditions.  In addition to 
this, the new setup required adequate shielding during high power operations for the 
safety of personnel working in the reactor area.  Figure 3-8 shows a schematic of the new 
TC access plug, highlighting the environmental control features and radiation shielding 





steel welded with carbon steel rod to minimize activation of the access plug during high 
power irradiations.  The majority of this activation results from the neutron capture of 
59
Co found in stainless steel.  When a neutron is incident on 
59
Co, neutron capture results 
in the formation of 
60
Co, a strong gamma emitter with a half-life of 5.27 years.  To avoid 
this potential source of radiation exposure to individuals working near the thermal 
column, as well as to minimize the non-specific irradiation of samples within the thermal 
column sample chamber, all steel used in the construction of the access plug was of the 
carbon variety.  The sample chamber at the core end of the access plug measures 13 cm x 
16 cm x 6 cm (5.11 in. x 6.30 in. x 2.36 in.) and is equipped with a thermocouple and 
inlet/outlet channels for gas flow around the sample.  The gas flows through 0.635 cm 
(0.25 in.) OD copper tubing and is coiled on the outlet end to increase the time before the 
gas is vented from the access plug.  This increases the time the gas is contained within the 
shielding and limits the release of radiation that results from neutron activation of the 
gases.  Surrounding the sample chamber is a coil of 0.953 cm (0.375 in.) OD copper 
tubing through which heated or cooled water flows to control the temperature of the 
sample chamber.  Similarly to the gas line, 15.24 m (50 ft.) of tubing is coiled within the 
access plug from the water outlet to limit the radiation levels external to the access plug.  
A temperature control unit which automatically responds to temperature fluctuations 
within the sample chamber during the irradiation is connected to the sample chamber 
thermocouple and water bath pump.  The temperature of the sample chamber is 
controlled by a relay switch which turns on/off water flow according to the desired 
conditions.  To provide adequate shielding during high power irradiations, the access 







Figure 3-8.  Schematic of environmental control thermal column access plug. 
 
In order to insert and remove the thermal column access plug efficiently, a support table 
was fabricated as shown in Figure 3-10.  The table is adjustable on 3 axes and equipped 
with ball bearings to allow easy movement of the access plug while seated on the table.  
The table is fixed in position on the exterior of the reactor wall, directly outside of the 











Figure 3-9.  TC environmentally controlled access plug with gas and water lines plumbed 
to the sample chamber.  The plug was filled with concrete to provide adequate radiation 














Chapter 4: Thermal Column Dose Mapping  
 
4.1  Thermal Column Neutron Spectrum Unfolding 
 
 
Proper characterization of a neutron field requires an understanding of the various 
neutron energies and their respective magnitudes within the field.  Generally, neutrons 
are grouped into three main energy regions known as thermal (slow), epithermal 
(intermediate), and fast.  Since neutrons are neutrally charged, the detection system 
always employs a reaction in which the neutron produces a charged particle or 
electromagnetic wave as a result.  The probabilities of these reactions are directly 
dependent on the incident neutron energy and each energy region is dominated by a 
specific cross section type.  The thermal regime is dominated by 1/√E and represents 
neutron capture resulting in activation or charged particle production, the epithermal 
regime is dominated by elastic and inelastic scattering as well as neutron capture 
producing rays, and the fast reactions are dominated by atomic reactions such as 
fission, (n,2n), (n,charged particle) production type reactions as well as elastic 
scattering.[61]  The techniques used to detect neutrons are divided into two 
subcategories, passive and active.  Active detection relies on nuclear reactions that emit 
an energetic charged particle as a result of interaction with a neutron.  The charged 
particle or recoiling nuclei directly ionize the detector material and the ionized material 
either emits light or the charge is collected on an anode.  The signal generated by the 
charged particle gives a real-time indication of the presence of incident neutrons.  









B-lined ionization chambers, 
6





Passive neutron detectors do not provide a real-time response.  These detectors “store” 
their response and can be read offline.  These include detectors such as track-etch, 
thermal luminescent detectors (TLD), and activation detectors.[61]  The track-etch 
detector relies on recoiling protons produced from neutrons scattering off hydrogen in 
poly(methyl methacrylate) (PMMA) to ionize and damage the PMMA, or other acrylic 
material, which is then etched in an organic solvent. The track path is preferentially 
etched and these tracks are then counted and correlated to neutron fluence and dose.  




LiF materials.  The probability of a 
6
Li(n,α) 
reaction is considerably large at thermal neutron energies, while 
7
Li has a non-existent 
(n,α) cross section.   Both types of TLD material are equally susceptible to gamma 
radiation.  The 
7
Li reading is subtracted from the 
6
Li reaction to give a total value of 
neutron fluence and dose.  However, both TLD and track-etch detectors only provide an 
integral response to the neutron fluence rate and possess no ability to divine neutron 
spectral information.  The last type of detector, the activation foil, can be used to quantify 
the energy-dependent neutron spectrum and neutron fluence rate.  In the activation foil 
technique, a series of isotopes are used whose cross sections are uniquely independent 
with respect to the incident neutron energy.  Each isotope is activated through a capture 
or charged particle production reaction and the resulting activation product is counted on 
a gamma ray detector, such as a High Purity Germanium (HPGe) detector.   The 
activation rate can be calculated after accounting for the exposure time and delay time 
between exposure and counting on the gamma ray detector, both of which are known to 
high certainty.  The most common passive detectors are thin foils and small diameter 





4.1.1  Neutron Detection by Activation Detectors 
 
 
The high neutron reaction cross section associated with thermal neutrons makes passive 
detection an ideal method for unfolding neutron spectra within thermalized neutron 
fields.  The foundation of this technique is based on the ability to induce radioactivity 
within a target material by exposing it to a field of thermal neutrons. One of the 
difficulties with measuring thermal neutrons is that most isotopes have a similar cross 
sectional shape in that neutron energy region.  Because the spectral unfolding technique 
described in the following section requires unique energy-dependent responses, a variety 
of activation techniques must be incorporated to form unique responses.  Despite this 
challenge, the activation technique offers one extreme advantage over other passive and 
active detection techniques, and that is because the passive activation foils responses do 
not change with respect to the neutron fluence rate.  Active detectors can often suffer 
from pulse pileup, where the detector cannot register the signal as fast as the incident 
neutrons arrive.[61]  In the activation technique, on the other hand, the detector decays at 
a known rate referred to as the half-life.  If the foil is counted within ~7 half-lives, the 
HPGe detector can statistically quantify the amount of material that is present.  In the 
following series of equations, this value of activity at time t can be used to determine the 
production rate,  ̇     This  ̇ value can then be used in the neutron spectral unfolding 
process to quantify the energy-dependent neutron spectra and total fluence rate.  As a 
note prior to beginning the derivation of the production rate, the notation of fluence rate 
rather than flux is adopted throughout the following sections to maintain compliance with 
the SI unit systems. Fluence rate has units of n/cm
2





given particle which passes through a given area per unit time.[62] 
 
The production rate,  ̇, is governed by the following equation: 
 
 ̇        (4-1) 
 
where  = energy-dependent neutron fluence rate  
 = energy-dependent microscopic cross section for the target reaction 
V = target material volume 
 
Therefore, the production rate is directly proportional to the neutron fluence rate.  As the 
target material is exposed to the neutrons, radioactive nuclei, N, formed from the nuclear 
reaction increase.  Once these radioactive nuclei are formed however, they begin to decay 
according to the decay constant for that particular nuclei.  The rate of change of 




  ̇        (4-2) 
 
where t = time 
 = decay constant 
 
When one multiplies the number of radioactive nuclei by the decay constant, λ, the unit 





with respect to N and multiplies by λ, one then achieves the activity, A, of the target 
material as a function of irradiation time, t: 
 
A(t)=  ̇(1-e-t)    (4-3) 
 
The activity of the target material will reach an equilibrium point, A, known as the 
saturated activity once the material is irradiated in a neutron field for an infinitely long 
irradiation time.  For irradiation times in excess of seven times the half-life of the 




)   (4-4) 
 
Upon removal of the target material from the neutron field, the induced radioactivity 
must be quantified.  From this point in time, the radioactive nuclei are no longer being 
produced in the target material due to the absence of neutron fluence.  The remaining 
radioactive nuclei continue to decrease by way of radioactive decay, hence the urgency to 
count the samples before the amount of activity falls below the minimum detectable 
activity of the detector system.  The number of counts, C, as registered by the gamma ray 





















       (4-5) 
 
where  = counting efficiency for a given gamma ray line 
B = background counts 
t1 = starting count time 
t2 = ending count time 
 











    (4-6) 
 
The equations discussed above assume that the activation product is not being activated 
further to produce a new product.  This assumption has been quantified and calculated for 
isotopes used in the neutron spectrum unfolding.  It was determined that the removal of 
the activation products through further activation is a negligible source of error and is 
therefore not necessary to consider in the calculations. 
 
The saturated activity can be used to calculate the production rate,  ̇.  The  ̇ value is then 
used to determine the magnitude of the neutron fluence rate.  The following figure 
demonstrates the activation and decay scheme for any given activation foil and is 
representative of the activity of the target material as a function of time throughout the 











As shown in formula 4-1, the production rate is directly influenced by the neutron 
reaction cross section of the target material.  The neutron cross section is not constant for 
all neutron energies, but rather varies as a function of the energy of the incident neutron.  
The fission cross section as a function of neutron energy for 
235







Figure 4-2.  
235
U fission cross section as a function of neutron energy. 
 
 
The cross section for each nucleus has unique variations as a function of energy, and by 
taking advantage of these variations it is possible to further unfold the energies of the 
neutron field beyond the broad thermal, epithermal, and fast regions.  By comparing the 
responses to a wide range of irradiated target materials, also referred to as detectors, with 
precisely characterized cross sectional spectra, a higher resolution of neutron energies can 































Gold 197Au 100 (n,) 98.66 198Au 2.69 d  0.411 95.6 
Copper 63Cu 69.17 (n,) 3.995 64Cu 12.7 h  0.511 35.2 
Scandiu
m 
45Sc 100 (n,) 24.06 46Sc 83.79 d 
0.889 100 
1.121 100 
Indium 115In 95.71 (n,) 181.6 116mIn 54.29 m 
1.294 84.4 
2.112 15.5 
Iron 58Fe 0.28 (n,) 1.153 59Fe 44.47 d  0.143 1.02 
Silver 
107Ag 51.84 (n,) 34.17 108Ag 2.37 m  1.649 97.15 
109Ag 48.16 (n,) 80.66 110Ag 24.6 s  2.892 99.7 
 
 
In order to provide enhanced neutron spectrum unfolding resolution in the epithermal and 
fast neutron regions, the use of threshold reaction is common.  These target materials 











































Cu 69.1 (n,2n) 
62
Cu 9.8 m 11.9 511 95 
65
Cu 30.83 (n,2n) 
64
Cu 12.7 h 11.9 511 37.8 
Nickel 
58
Ni 68.08 (n,2n) 
57
Ni 36 h 13 1370 86 
58




1.9 810.77 99.45 
Indium 
115
In 95.71 (n,n’) 
115m
In 4.49 h 0.5 336.3 46.7 
Titanium 
46




5 889.25 99.98 
1120.5 99.99 
47
Ti 7.44 (n,p) 
47
Sc 3.35 d 1.35 159.4 68 
48
Ti 73.72 (n,p) 
48




Fe 91.75 (n,p) 
56
Mn 2.58 h 4.9 840 99 
54




0.8 834.8 100 
Magnesium 
24



















Au 100 (n,2n) 
196




Zn 48.8 (n,p) 
64
Cu 12.7 h 2 511 37.8 
Cobalt 
59
Co 100 (n,) 
56
Mn 2.58 h 5.2 840 99 
Tungsten 
182








And finally, the addition of resonance absorbers and neutron filters enables further 
customization to the unfolding of a neutron spectrum.  By combining these materials with 
thermal neutron and threshold targets, finely tuned neutron energies can be extracted 
from the continuous spectrum of energies present in the neutron field.  Table 4-3 provides 
































Zirconium 2 8    
Europium 0.1 1    
Iron 1 4    
Silver   
4 10 3.00E+04 
10 11 2.00E+03 
Bismuth   
600 1050 1.00E+02 
1150 2250 2.00E+01 
Cadmium   0.1 0.6 1.00E+04 
Indium   1 3 3.00E+04 
Uranium   
4 8 1.00E+04 
10.5 12 1.00E+04 
12.5 13.5 1.00E+04 
 
 
To further illustrate this concept, Figures 4-3 through 4-5 provide simulated detector 










Figure 4-4.  Energy-dependent neutron reaction rates for various activation foils 






Figure 4-5.  Energy-dependent neutron reaction rates for gold foils with various 
combinations of resonance absorbers and neutron filters highlighting the change in 
detector response below 1 eV. 
 
A second method of integrating passive detection into neutron spectrum unfolding is the 
moderate and capture technique.  Expanding upon the original designs of Bramblett, 
Ewing and Bonner, a moderate and capture technique was designed for quantifying the 
energy-dependent neutron fluence rate where the neutrons were known to emanate into 
the detector from one direction.[63]  Rather than using resonance absorbers and neutron 
filters to shield target materials from certain neutron energies, the moderate and capture 
technique utilizes a series of detectors embedded in various thicknesses of neutron 
moderating material.   This technique was used to supplement the resolution of resonance 









Figure 4-6.  Schematic of the moderate and capture technique for neutron detection. 
 
 
Because neutrons are thermalized efficiently by high hydrogen content material, varying 
thicknesses of hydrogenated materials provides varying degrees of neutron moderation.  
As a neutron field is incident on the target, neutrons are absorbed in the target material or 
scattered and thermalized within the moderator and continue through the detector system.  
Because the neutron absorption cross section for 
197
Au is approximated as 1/√E with a 
higher value for lower neutron energies, neutrons with lower initial energies will be 
absorbed in the first foils while higher energy neutrons have a lower probability of 
capture and will continue to the next hydrogenous layer.  After continuing further into the 
detector system, neutrons have a probability to be scattered and further thermalize.  As 
the neutrons scatter within the PMMA, energy is transferred from the neutrons to the 
moderating material.  The continuation of this scattering process results in a steady 
decrease of neutron energy as a direct function of the thickness of moderating material 
traversed.  As the neutrons continue to thermalize, the probability of absorption by the 
target gold foil increases.  Each layer of PMMA results in a further thermailzation of the 





results in a unique energy-dependent response.  These unique responses, in concert with a 
known response matrix, are used in conjunction with the resonance shielding covered 
foils to unfold the thermal component to the neutron spectrum.   
 
It is important to note that the directional detector system is succeptable to neutron 
scattering into the detector system from outside.  This can lead to uncertainty and 
measurement error.  Uncertainty due to neutrons that scatter into the detector system and 
result in activation of the foils has been minimized through careful design and 
engineering.  This was accomplished by encapsulating the sides and rear of the unit in 
boral and cadmium, as both materials posess extremely large thermal neutron absorption 
and capture cross sections.  The high thermal neutron capture cross sections of boral and 
cadmium prevent scattered neutrons from entering the downstream regions of the 
moderate and capture detector system without first passing through the acceptance 
aperature and entering the detector PMMA moderator region. 
  
4.1.2  Analysis of Activation Detector Responses 
 
 
Prior to analyzing the induced radioactivity within the detectors, the HPGe detector was 
calibrated with a NIST-traceable multi-nuclide calibration source to determine the 
detector efficiency at various photon energies.  This energy-dependent detector efficiency 
is factored in at  in formula 4-5.  An HPGe spectrum of the NIST-traceable multi-







Figure 4-7.  HPGe detector response for multi-nuclide calibration source. 
 
The spatial distribution of the neutron fluence rate profile across the face of the thermal 
column access plug sample chamber was determined by irradiating a field of indium 
wires positioned along the planar window perpendicular to the dominant neutron field.  
The grid of indium wires was irradiated and analyzed to determine the production rate as 
a function of position within the neutron field.  Figure 4-8 shows the spatial distribution 





















Figure 4-8.  Normalized neutron fluence rate spatial distribution across the face of the 
thermal column sample chamber. 
 
 
Analysis of the spatial profile of the neutron field across the face of the thermal column 
access plus reveals that the relative standard deviation across all regions of the TC sample 
chamber face is 13.8%.  The peak fluence rate location is a factor of 1.78 higher than the 
lowest region.  The thermal neutron fluence rate is maximal in the center region of the 
plug face.  Scattering of thermal and epithermal neutrons in the air, water, and concrete 
filled sections surrounding the sample chamber contribute to an increased thermal 
neutron distribution within the center of the chamber.   
 
After establishing the presence of a relatively uniform spatial distribution of neutrons in 
the sample chamber, there are two key correction factors that must be accounted for 
before unfolding the neutron spectrum.  The first correction factor that must be applied to 








thermal column of the MUTR. The calibration energy-dependent response matrix used in 
the analysis assumes a mono-directional neutron field passing directly along an axis on 
the face of the detector with the field incident on the acceptance aperture.  The anisotropy 
of the neutron field resulting from a neutron beam thermalized with a graphite moderator 
must be determined in order to apply the appropriate correction factor to the experimental 
response matrix selection.[64]  Energy-dependent response matrices were calculated for a 
series of angles and the experimental response matrix used for unfolding is the 
superposition of the responses of the varying degrees of anisotropy.  These angular 
dependencies were calculated at discrete angles and superimposed as Green’s Functions 
to the solution set.  The angular dependence of the neutron field was measured by 
irradiating neutron foils arranged at 0, 22.5, 45, 77.5, and 90 degree angles with respect 









Figure 4-9.  Schematic of foil placement to determine angular dependence of the neutron 
field within the thermal column. 
 
The second correction that must be applied to properly analyze the passive detector 
response relates to the uniformity of the temporal component of the neutron field 
throughout the irradiation.  Due to the operational nature of the nuclear reactor, a 
continuous temporal approximation of the reactor power and hence, neutron fluence rate, 
cannot be applied. The ramp up insertion of reactivity and scram insertion of negative 
reactivity upon initiation and cessation of the irradiation contribute to a non-uniform 
neutron field and are not instantaneous.  For longer duration irradiations, this uncertainty 
is relatively small.  On the other hand, irradiations of a few minutes are greatly impacted 
by this ramp up and down.  To account for this, a 
3
He neutron detector was placed in the 
west beam port experimental facility as a time-integrating power rate meter during the 





neutron fluence rate.  Using a piece-wise continuous integration technique, each time bin 
(binned in 1 s intervals) was used to quantify the temporally-dependent relative neutron 
fluence rate.  Utilizing the power fluctuations recorded by the neutron detector system, 
the activity responses can be corrected.  A sample power history as a function of time is 
shown in Figure 4-10. 
 
 
Figure 4-10.  Sample power history recorded during the irradiation of detectors in the 
MUTR thermal column. 
 
The critical concept of few channel neutron spectral unfolding is the use of several 
selected detector responses (i.e. activation foils) and, through a mathematical process, 
solving a series of ill-posed problems that result in a multi-channel energy-dependent 
neutron response.  The activation foils themselves do not directly provide the energy-
dependent neutron spectra.  Each detector is an “integral” detector that has a response 
which is not unique to only one neutron energy.  The output of production rate, (n,γ) 
reactions, (n,α) reactions, etc. does not provide the energy-dependent response.  The 













response of a given activation foil, be it moderate and capture or resonance self-shielding, 
to a given neutron spectrum is given by the first order Fredholm integral equation of the 
first kind: 
 
  ̇  ∫   ( ) ( )                    
 
 
     (4-7) 
 
where   ̇i = production rate of isotope i from parent x of the ith detector 
arrangement/position  
Ri(E) = response function for the ith detector at energy E  
  (E) = energy-dependent neutron fluence rate in n/cm2/s 
 
This continuous energy distribution form of the Fredholm integral equation can be 
converted to a more simplistic matrix form of the solution, which can be more easily 
solved numerically.   
 
  ̇  ∑                              
 
        (4-8) 
 
where   g = group flux between Eg and Eg+1 (total measure of neutron fluence between the 
upper bound energy Eg+1 and the lower energy bound Eg) 
Ri,g = multi-group form of the ith detector response 
 
This system can produce a multi-group energy-dependent neutron spectrum.  However, 





the number of equations (possible unique activation detectors) are such that the matrix 
equation is underdetermined (i.e. there is no unique solution to the series of equations) 
because the total number of unknowns (neutron energy bins) outnumbers the number of 
unique energy-dependent detectors.  This is particularly true in the low thermal energy 
neutron region where there are no unique datasets without further engineering work.  This 
is the dominating reason for combining the moderate and capture technique with the 
resonance self-shielding technique.  Each system provides a unique piece of data with a 
unique energy-dependent response.   
 
The unique energy-dependent response matrix for each foil in the moderate and capture 
system, as well as the resonance self-shielding system, were calculated using an industry 
standard, continuous energy, combinatoric geometry Monte Carlo N-Particle transport 
code, MCNP version 5 (MCNP5).   This code has been used in numerous other works to 
produce the energy-dependent response matrix.[65-67]  
 
The response matrices calculated in MCNP5 were then loaded into a maximum entropy 
unfolding program, MaxEd-FC33.[68, 69]  Since the above Fredholm integral equations 
are underdetermined, an iterative solution process is seeded initially with a “starting 
spectrum”.  There is significant concern over the starting spectrum imparting too much 
“information” into the unfolding code sets.  This is often considered operator influence.  
A significant effort by the collaborators on this project was put forth to improve the 
method to generate this starting spectrum, while removing operator influence.  The 





RATE.  RATE builds off previous work by Dr. Reginatto on a Bayesian Statistical 
Estimator (BSE) for predicting starting neutron spectra and was completed by Dr. Burgett 
in early 2008.  RATE utilizes the BSE by employing a Monte Carlo Markov Chain 
(MCMC) statistical analysis of the responses of the detector data.  The MCMC and BSE 
utilize user supplied physical parameters of the system to constrain the initial spectrum 
used to seed the maximum entropy unfolding technique.  The physical parameters are 
dictated by the physics of the problem.  In any given fission environment, there is a 
distributions of neutrons known as the chi-nu distribution, which resembles a skewed 
Gaussian.  In an environment with a hydrogenous or light isotope moderator, there is a 
thermal neutron peak which is approximated as a Gaussian.  In fast neutron systems such 
as cosmic, atmospheric, galactic, and accelerator produced neutron sources, there are two 
high energy evaporation and spallation peaks which are approximated as skewed 
Gaussian peaks.  Lastly, there is a continuum function which is a smoothed trapezoidal 
shape of neutrons thermalizing from high energies to thermal energies.  In the absence of 
intense resonance absorbers (significant quantitates of Cd, 
238
U, Ag), the neutron 













Table 4-4.  Physical parameters used to fit the RATE code starting neutron spectrum. 
Feature Number of Parameters to Fit Parameters 
Thermal Peak 2 Energy, FWHM 
Epithermal Continuum 5 Low Energy, Slope, High 
Energy, Slope, connection 
slope 
Fast Peak 3 Energy, FWHM, skewness 
Evaporation Peak Not Applicable  
Spallation Peak Not Applicable  
 
 
From Table 4-4, it can be seen that the RATE program needs ten detector responses in 
order to create a piecewise continuous and smooth starting neutron spectrum which is 
constrained by physics.  In the Figure 4-11, note that Gaussians 1-3 were omitted from 








Figure 4-11.  Sample starting neutron spectra generated using the RATE code. 
 
The MCNP5 calculated response matrices were prepared for insertion into the 
MXD_FC33 unfolding code.  These matrices were calculated as parallel beams of 
neutrons as a function of angle with respect to the axis of the detectors.  A sample 
computed response is shown in Figure 4-12.  Note the predicted detector response as a 
function of both incident neutron energy and thickness of moderator between the neutron 












































Figure 4-12.  Computed energy-dependent neutron spectral responses of the moderate 
and capture detector system for a parallel beam of neutrons incident on the face of the 
detector. 
 
The experimentally measured activation rate of the target gold foils as a function of 
moderator thickness is shown in Figure 4-13.  As expected for a highly thermalized 
neutron field, the activation rate is maximal for the foils closest to the moderate and 
capture entrance aperture.  For a neutron field with a higher proportion of epithermal and 
fast neutrons, the plot of activation rate as a function of moderator thickness would yield 






Figure 4-13.  Activation rate on the gold foil within the moderate and capture detection 
system as a function of PMMA moderator thickness. 
 
 
The starting spectrum from the RATE package and the calculated response matrices from 
MCNP5 are loaded in MXD-FC33.  The problem is then iterated until a smooth response 
with an overall uncertainty of less than 1% is achieved.  This is determined from the chi-
squared value of the neutron spectrum and Rcalc/Rmeas, and minimizing these values to 1.  
Rcalc/Rmeas is a measure of the calculated response of detector I, if one integrates the 
unfolded neutron spectrum against the energy-dependent cross section versus the 
measured value.  If the spectrum were perfectly precise, the result would be 1 for every 
detector.  However, this is never the case and the result is usually minimized to within 
1%.   
 
y = 2.5175E-02e-9.9559E-03x 































Figure 4-14.  Flowchart depicting the progression through MCNP5 modeling to RATE 
starting spectrum creation, response matrix insertion, MAXED operation, and the 
resulting unfolded neutron spectrum. 
 
Independent of the detector modeling and experimental analysis, the neutron spectrum 
within the MUTR thermal column was modeled with MCNP/MCNPX.  A detailed 
description of this model and the uncertainties associated with determination of the 







Figure 4-15.  MNCP model of the MUTR core and experimental facilities. 
 
In the results section of this chapter, the unfolded neutron spectra generated from the foil 
activation technique and MCNP model of the MUTR are discussed.   
 
As a point of clarity, it is important to note that there are two distinct MCNP models 
discussed in the preceding section.  The first MCNP model is utilized by the MAXED 
software package to quantify and unfold the neutron spectrum in conjunction with the 
experimentally measured detector responses and RATE starting spectrum.  The MCNP 
model simulates the detector responses as a function of a continuous spectrum of neutron 
energies incident upon the detector.  The second MCNP model was created to simulate 
the entire MUTR core and experimental facilities as a whole.  The geometries and 
materials within the core were programmed and predict the behavior of the neutron 





sectional data for all material within the reactor core and experimental facilities, the fate 
of the neutron population is predicted at a final region of interest. 
 
4.1.3  Results 
 
The unfolded neutron spectrum generated by passive detector activation was compared to 
the MNCP calculated spectrum.  As shown in Figure 4-16, the neutron lethargy fluence 
rates for the two methods are in close agreement.  The neutron fluence rate within the 
entire energy spectrum (10
-9 
– 16 MeV) was within 5%, when comparing the 
experimental measurements with the MCNP/X computed model.  Within the < 3 eV 
neutron energy range, results of the two methods were also within 5%.  The third data set 
in Figure 4-16 depicts the neutron spectrum as measured within the thermal column 
sample chamber with the steel cover installed.  As expected, the steel cover has a 
significant impact on the fluence rate magnitude at low neutron energies due to the large 
1/√E dependence of the iron cross sections.  In order to provide equivalent total neutron 
fluence to a sample within the thermal column plug, irradiation times would have to 
increase by a factor of 1000 should the cover be installed.  With this in mind, thermal 
neutron irradiation of the BNCT target cells was performed without the cover installed. 
  
When unfolding neutron spectra, it is common to replace the energy variable with 
neutron lethargy, u.  Lethargy is defined as a decrease in neutron energy and is a common 
term used in the reactor physics community.  As a neutron collides with material and 
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)   (4-9) 
 
The total neutron fluence rate within a specific incremental lethargy interval is 
proportional to the neutron fluence rate in the corresponding energy interval, thus 
providing a means of converting the unfolded neutron fluence rate per unit lethargy into 
the neutron fluence rate.   
 
(u) = E(E)    (4-10) 
 
The comparisons were made in lethargy fluence rates primarily because the reference 







Figure 4-16.  Comparison of the experimental unfolded spectrum, MCNP calculated 




Figure 4-17 provides a more detailed view of the neutron energy spectrum shift when 
comparing the MCNP calculated results and the experimental activation unfolding in a 
log-linear plot.  The plot area conversion between lethargy fluence rate and neutron 






























































































Figure 4-18.  Neutron fluence rate spectrum of the MUTR thermal column. 
 





energy range) between the MCNP calculations and the experimentally obtained results.  
The experimental results show a slight neutron “cooling” where the thermal peak is 
shifted slightly to lower energies and is negatively skewed.  The presence of a 
hydrogenous sample chamber surrounding the neutron detectors in the experimental 
measurement contributed to further thermalization of the neutron field that was not 
accounted for in the computer model.  In addition, neutron scattering within the thermal 
column experimental facility is largely dependent on the molecular motion of hydrogen, 
whereby small discrepancies in temperature can shift the Gaussian distribution of thermal 


































bands, however, integral neutron fluences over larger energy regions decrease this 
uncertainty.   
 
The thermal neutron (< 3 eV) fluence rate at 250 kW in the sample chamber of the 




/s.  Thermal 
neutrons represent 94.6% of all neutrons within the sample chamber.  This thermal 





 in a 20 minute irradiation within the sample chamber. 
 
Uncertainty in the experimental unfolding of the neutron spectrum is dominated by 
measurement uncertainties associated with detector analysis.  Radioactivity decay 
schemes, determination of target atoms in a foil/wire, energy calibration of the multi-
channel analyzers, irradiation and delay times, and cross sectional data all provide their 
own sources of uncertainty.  The IQU_FC33 software package within MAXED permits 
error propagation throughout the deconvolution process.  The relative error in spectral 
unfolding is estimated to be less than 3%.  The experimental unfolding process was 
performed using NIST-calibrated 
252




AmBe sources and 
yielded a response within 2% of the accepted value.  Further discussion of neutron 
spectrum unfolding uncertainty is provided by Dr. Burgett.[71]  Techniques utilized to 









4.2  Modified Ion Chamber Measurements of Thermal Neutrons 
 
 
4.2.1  Introduction to Ionization Chambers 
 
 
Ionization chambers are a type of detector used to measure the direct ionization of gas.  
As charged particles travel through a gas, positive ions and free electrons (ion pairs) 
formed in the gaseous molecules are collected on electrodes within the ionization 
chamber.  The electric field in the ionization chamber is created by a voltage potential 
imposed between the two electrodes.  As the ion pairs are collected on the electrodes of 
opposing polarity, an electrometer is utilized to measure the current within the chamber.   
 
In order for ionization to occur, the incident charged particle must impart sufficient 
energy to dissociate electrons from the shells of the gas molecule.  The magnitude of 
energy required for the ionization of most gases is in the 10 to 20 eV range.  The average 
energy lost by a charged particle as it travels through gas per ion pair formed, known as 
W-value, is higher than the ionization energy of the specific gas.  This phenomenon is 
explained by the various mechanisms of energy distribution within the gas.  For example, 
a charged particle may lose energy through an excitation interaction prior to the 
formation of an ion pair.  In this case, the initial energy of the incoming particle must, at 
a minimum, equal the sum of the energies imparted in the excitation and ionization 







Table 4-5.  Summary of various W-values for common ionization chamber gases. [72] 
 W-value (eV/ion pair) 
Gas Fast Electrons Alpha Particles 
He 32.5 31.7 
H2 38.0 37.0 
N2 35.8 36.0 
Air 35.0 35.2 
O2 32.2 32.2 
CH4 30.2 29.0 
 
 
A cavity ionization chamber consists of a solid structure surrounding a gas-filled volume.  
Within the field of cavity chambers, a fully guarded thimble-type chamber is designed 
with a cylindrical wall (0.1-3 cm
3
 volume) surrounding a gas-filled volume and ion 
collector, as shown in Figure 4-19.  A high voltage potential is applied between the 













4.2.2  Materials and Methods 
 
The measurement of thermal neutron capture by 
10
B within the MUTR thermal column 
was investigated with a pair of Exradin ion chambers from the Fermilab Fast Neutron 
Therapy facility.[74, 75]  The ion chambers are Spokas thimble-type with a collecting 
volume of 0.5 cm
3
 and A150 plastic wall material.  A150 plastic is designed to simulate 
the International Commission on Radiation Units and Measurements (ICRU) 
representation of soft tissue response to irradiation with photons and neutrons of varying 
energies.  The composition of A150 plastic by weight fraction is 10.1% H, 77.6% C, 
3.5% N, 5.2% O, 1.7% F, and 1.8% Ca.  The two ion chambers are structurally 
equivalent; however, the wall material of one chamber is loaded with 1000 ppm natural 
boron (184 ppm 
10
B).   The ion chambers were filled with air and +400 V potential was 
applied to each during the irradiation.  A Keithley 617 electrometer was used to measure 
the current formed in each chamber. 
 
Within each ion chamber, ion pair formation is the result of interactions between photons, 
neutrons, and charged particles.  For the two ion chambers, photons and fast neutrons 
produce ion pairs through equivalent interactions.  Specifically, recoil nuclei and ions 
from fast neutrons and secondary electron formation from incident photons and charged 
particles result in ionizations within the chamber volume.  However, the response to 
thermal neutrons varies between the borated and non-borated chambers.  In the borated 














capture reaction with thermal neutrons, but does not contain the boron atoms necessary 








Li reaction within the 
MUTR thermal column was investigated for reactor power levels ranging between 50-
250 kW.  For each power level, charge collected over 30 seconds was measured in 
triplicate.  The range of power levels provided information about both the presence of 
thermal neutrons within the thermal column, as well as an indication of the proportional 
increase in thermal neutrons as reactor power was increased.   
 
 
Figure 4-20.  Ion pair formation as a function of reactor power for the standard A150 and 
boron-doped chambers.  As reactor power increases, the dose enhancement from boron 
capture of thermal neutrons remains constant at approximately five times the non-borated 
response.  30 second measurements were taken in triplicate at each power level.  Data 




To ensure that the ion chambers have an equivalent response to photons, the chambers 









































and 1.33 MeV rays emitted from the 2.1 kCi 
60
Co source.  The chambers were placed 
91 cm (35.8 in.) from the source top hat.  Charge collected over a 30 second interval was 
measured in triplicate.  The responses of the two ion chambers were within 3%, and the 
variation can largely be attributed to the volume discrepancy between the two 
chambers.[75] 
 
4.3  Ion Chamber Measurements of Gamma Ray Radiation Field 
 
4.3.1  Gamma Field Dosimetry  
 
 
The Bragg-Gray cavity theory states that the energy deposited within a gas-filled cavity, 
assuming the cavity is sufficiently small such that it does not change the distribution of 
electrons in the medium without the presence of the cavity, results solely from the 
electrons passing through the cavity itself.  This assumption lends to the following 
equation: 
 
Ev = Jv * W *    

where Ev = energy absorbed per unit volume of the medium 
Jv = ionization per unit volume produced in the gas 
W = average energy lost by the secondary electrons per ion pair formed in the gas 






The total charge collected by the ion chamber, Q, is directly related to the fill gas within 
the chamber cavity.  The ratio of ionizations in two gases (x and y) can be determined by 
the following equation[76]: 
 
Qx/Qy = (S/)x/(S/)y * Wy/Wx * x/y (4-12) 
 
where (S/r) = mass stopping power of the gas 
 
 
Temperature and pressure must be accounted for when comparing detector responses 
from the calibration environment to the environment of the experimental measurements.  
The correction factor, F, for temperature and pressure is calculated by: 
 
   
(     )
   
 
   
 
    (4-13)   
 
 where T = temperature, 
o
C 
 P = pressure, mm Hg (torr) 
 
It is important to note that the relative humidity is not included in the correction factor.  
This is because the detector response is nearly uniform in the humidity range of 15-
80%.[77]   
 
The air kerma calibration coefficient, NK, for a specific ion chamber is the quotient of the 





from the chamber, corrected to the density of the air at 1 atm and 22
o
C.   The ion 
collection efficiency, Aion, is determined using the following equation[78]: 
 
Aion = 4/3 – (1/3 * I1/I2)   (4-14) 
 
where I1 and I2 = ion currents at nominal (300 V) and half (150 V) potential 
 
4.3.2  Materials and Methods 
 
The absorbed dose from rays within the thermal column of the MUTR was measured 
with an IC-18G ion chamber (Far West Technology, Goleta, CA).  The IC-18G is a 
graphite walled 0.1 cm
3
 cylindrical ion chamber with a wall density of 300 mg/cm
2
 and 
thickness of 0.064 cm.  Calibration of the ion chamber was performed to NIST-traceable 
standards in a 
60
Co field at the University of Wisconsin Accredited Dosimetry Calibration 















Table 4-6.  NIST-traceable calibration values and parameters for the IC-18G ion 
chamber. 
Field Size 10 x 10 cm at 100 cm distance 




Calibration Uncertainty  1.5% 
Ion Collection Efficiency (Aion) 1.000 
Air Kerma Calibration Coeff. 2.337x10
8
 Gy/C 






Pressure 736.5 Torr 
Relative Humidity 22% 
 
 
The ion chamber was positioned in the thermal column of the MUTR during a 250 kW 
steady-state operation.  CO2 gas flowed through the chamber volume at 1.5 cc/min.   
 
4.3.3  Results 
 
The results of the gamma dose rate measurements within the MUTR thermal column at 
250 kW are summarized in Table 4-7. 
 
Table 4-7.  Gamma ray dose measurements within the MUTR thermal column at 250 kW. 
Thermal Column MUTR 250 kW 
Nk(g)co2 1.51E+08 (Gy/C) 
   Temp 19 oC 
Pressure 766.9 Torr 
PT Correction 0.988669 
 ECP 1.001 
 
   Chamber Current 6.32E-11 (C/min) 







Measurements of the charge collected by the ionization chamber over a 30 second period 
were performed in triplicate at 250 kW.  The average response was 0.0632 + 0.004 










Chapter 5:  Liposomes   
 
 
Lipids are organic compounds that contain esters of fatty acids and are usually insoluble 
in water.  There are many categories of lipids, including: glycerolipids, 
glycerophospholipids, sphingolipids, etc.  The most common lipids found in cell 
membranes are phospholipids known as phosphatidylcholines (PC).  PCs contain a 
choline headgroup (hydrophilic) and glycerophosphoric acids bonded to a fatty acid 
(hydrophobic); and are capable of forming lipid bilayers.  When lipids are dispersed in an 
aqueous solution, vesicles containing an inner volume of aqueous solution surrounded by 
a lipid bilayer membrane are spontaneously formed.  These vesicles are known as 
liposomes, as shown in Figure 5-1.  Within the liposome membrane, a bilayer of lipids 
forms due to the hydrophobic interactions of the fatty acid chains and the hydrophilic 
nature of the choline headgroups.   
  
 
Figure 5-1.  Schematic diagram of a liposome illustrating the aqueous inner and outer 






As a method of targeted drug delivery, liposomes are capable of facilitating introduction 
of both hydrophilic and hydrophobic compounds.  In the former instance, the drug is 
added to the aqueous solution and mixed with the lipids during hydration.  Hydrophilic 
compounds are encapsulated in the aqueous inner volume of the liposome and remain 
within the liposome vesicle until delivery to the target site.  In the latter instance, 
hydrophobic compounds are mixed in with the lipids and entrapped within the lipid 
bilayer.  Due to the hydrophobic nature of BCH, loading into the liposomes occurs during 
the lipid dissolution phase. 
 
While the formation of liposomes is a spontaneous result of mixing lipids with aqueous 
solutions, size, structure, and encapsulation efficiency can be greatly impacted by the 
method of liposome preparation.  The various means of preparation rely on a difference 
in methodology for dispersing the lipids within the aqueous solution and are divided into 
physical dispersion, two-phase dispersion, and detergent solubilization.[79]  Based on 
previously reported success for intracellular delivery of BCH, compatibility with 
biological molecules, ease of use, and desired liposome size distribution, the French 
pressure cell procedure of mechanical dispersion was chosen.[42-44, 79]  The French 
pressure cell was one of the first methods developed for preparing liposomes[80, 81] and 
facilitates the conversion of large multilamellar vesicles (LMVs) to intermediate-sized 
unilamellar vesicles (IUVs) and small unilamellar vesicles (SUVs)  by pressurizing a 
liposome solution and slowly forcing the solution through a small outlet orifice.  As the 
solution passes through the orifice, the shear forces fracture the structure of the LMVs 






Figure 5-2.  Schematic diagram of the French pressure cell used to convert LMVs to 
IUVs and SUVs.[79] 
 
Throughout this fractionation and reformation, the LMVs are transformed into IUVs and 
SUVs.  This process relies heavily on extreme force applied to the LMVs and because of 
this is, it vital that the solution be subjected to high pressure.  The final size of the 
reformed liposomes is directly proportional to the pressure exerted as the solution passes 







Figure 5-3.  The direct relationship between pressure exerted on the liposome at the exit 
orifice of a French pressure cell and the mean vesicle size.  As pressure is increased, the 
mean vesicle size decreases.[79] 
 
5.1  Synthesis of Liposomes and Size Reduction 
 
Liposomes were prepared using 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
(850355P, Avanti Polar Lipids Inc., Alabaster, AL), cholesterol (CHOL) (700000P, 
Avanti Polar Lipids Inc., Alabaster, AL), and cholesteryl 1,12-dicarba-closo-
dodecaboranel-carboxylate (BCH).  55.0 mg DPPC, 9.8 mg CHOL, and 5.5 mg BCH 
were added to a 25 mL round-bottom flask.  The 0.33:1 cholesterol:phospholipid molar 
ratio was selected based on previous experiments for incorporation of BCH into liposome 
formulations, and research involving the incorporation of lipophilic drugs into lipid 
bilayers.[79, 82, 83]  The lipids were then dissolved in 6 mL of 2:1 (v/v) 
chloroform:methanol (Sigma-Aldrich, St. Louis, MO).  The lipid mixture was dried using 
a rotary evaporator (Rotavapor R-210, Buchi Labortechnik AG, Switzerland) and heating 
bath (B-491, Buchi Labortechnik AG, Switzerland) set to 60 rpm for approximately one 
hour at 60
o





mL of PBS (pre-heated to 60
o
C) with 500 mg of glass beads (11-312C, Fisher Scientific, 
Pittsburgh, PA) were added to the flask and stirred in a water bath at 60
o
C and 120 rpm 
for two hours.  Throughout the hydration process, the mixture was kept at 60
o
C to avoid 
falling below the phase transition temperature (Tm) of the lipids.   
 
 
Figure 5-4.  Chemical structures of DPPC, cholesterol, and BCH. 
 
The hydrated liposome formulation contains LMVs with a large size distribution.  In 
order to reduce the size of the LMVs and create IUVs and SUVs, the formulation was 
processed by high-pressure homogenization (EmulsiFlex-B3, Avestin Inc., Ottawa, ON, 
Canada).  In this process, 3.5 mL of liposome formulation was injected into the sample 
chamber and the chamber was sealed by closing the plug and set cap.  The unit was 
connected to a pressurized air source and set to an inlet pressure of 100 psi using the 
built-in regulator.  This correlates to a hydraulic pressure of 20,000 psi within the sample 
chamber, as reported by the manufacturer.  The homogenizer was placed in “pump” 
mode and the sample chamber was pressurized.  Slowly, the set cap was released to allow 
the liposome formulation to pass through the discharge tubing.  This process results in a 
slow, steady release of the formulation from the sample chamber, with a manufacturer 
recommendation of approximately 1-2 minutes to release 3.5 mL of sample solution.  
Upon completion of the release, the set cap was tightened and the unit was placed in 





sample chamber. This process was repeated for 1-2 cycles.   Liposomes were stored at 
4
o
C until use. 
 
 
Figure 5-5.  Avestin B3 high-pressure homogenizer. 
 
5.1.1  Lipid Oxidation 
 
 
Lipid oxidation is a degradation process whereby a hydrogen atom is removed from a 
carbon atom adjacent to a double bond, resulting in the formation of a free radical (alkyl 
radical).  In the presence of oxygen, this alkyl radical propagates to form a peroxyl 
radical.  Peroxyl radical interaction with another hydrogen atom of a neighboring lipid 
yields a lipid peroxide molecule and lipid radical, which in turn undergoes the 
propagation step of peroxyl radical formation. In the absence of radical scavengers, 
termination of the radical formation occurs when the increased presence of free radicals 
is sufficient such that the probability of two radicals interacting together results in a 







Figure 5-6.  Mechanism of autoxidation in unsaturated fatty acids.[84] 
 
Unsaturated fatty acids are most susceptible to the initiation of an alkyl radical due to the 
delocalization of the hydrogen atom along the fatty acid chain.  Because of this, saturated 
lipids are far less prone to oxidation.  Oxidation of cholesterol and cholesteryl esters is 
possible given the unit of monounsaturation within the carbon 5,6 positions, and occurs 
by a similar mechanism. 
 
Oxidative damage to the cholesterol and cholesteryl esters can result in the presence of 
epoxides, peroxides, and diols, as well as decreased stability of the liposome structure.  It 
is important to note that liposome integrity is less critical in drug delivery systems which 
incorporate the lipophilic drug within the lipid bilayer.  Degradation of the lipids by 
oxidation often results in the leakage of aqueous material from within the encapsulated 





delivered to the target system.  Lipophilic drugs incorporated in the lipid bilayer, on the 
other hand, are less likely to release from the liposomes as a result of membrane 
instability.     
 
The selection of DPPC as the principle lipid within the BCH liposomes minimized the 
potential for oxidative damage due to the saturation of the fatty acid chains.  However, 
the presence of cholesterol and BCH warrant caution in storage and liposome preparation 
to minimize oxidation during synthesis of the liposome formulation.  Lipids were stored 
in glass containers at -20
o
C in the dark.  Secondary containers with desiccant were 
utilized during storage and upon removal for liposome preparation.  Dry lipids were 
warmed to room temperature prior to dissolution in the lipid mixture.  Once hydrated, the 
liposome formulation was sealed and stored in the dark at 4
o
C prior to incubation in the 
cell medium.  Liposome formulation was prepared no more than 24 hours prior to 
incubation with the cell cultures.  Size analysis with dynamic light scattering of the 
liposomes did not reveal any change in structure or size after one week in storage.  In 
addition, abiding by proper storage protocol yielded no change in the physical appearance 











5.2  Liposome Size Analysis 
 
5.2.1  Introduction to Dynamic Light Scattering 
 
 
Size analysis of BCH-containing liposomes was accomplished using light scattering.  
This technique relies on the Rayleigh scattering of light by a molecule or particle as light 
passes through and induces a momentary dipole. In dynamic light scattering (DLS), also 
commonly referred to as photo correlation spectroscopy (PCS) or quasi-elastic light 
scattering (QELS), a photon beam is incident upon particles in suspension and the 
intensity of the scattered light is measured as a function of time.  Movement of the 
particles in suspension is a result of Brownian motion and leads to time-dependent 
fluctuations in the scattered light intensity due to the constructive and destructive 
interference of the surrounding particles.  The fluctuations in scattered light intensity are 
directly proportional to the diffusion rate of the particles in suspension, and are quantified 
in a second order correlation function: 
 
 ( )( )  
  ( ) (   ) 
  ( )  
    (5-1) 
 
where I(t) =  intensity of the scattered light at time t 
 = delay time.     
 
For short delay times, there is a very high correlation because the particles have not 





time is increased, the correlation decays exponentially as a result of diffusion of the 
particles.  The correlation function is then used to determine the decay rate: 
 
 ( )( )             (5-2) 
 
where B = baseline of the correlation function at infinite delay 
correlation function amplitude at zero delay 
decay rate   
t = time 
 
From the decay rate, the diffusion coefficient, Dt, can be derived with the equation: 
 
         (5-3) 
 
where q = magnitude of the scattering vector 
  
    
 
    (  ⁄ ), with no the solvent index of refraction, o the vacuum wavelength of 
the incident light 









From the Stokes-Einstein equation, the diffusion coefficient is used to calculate the 
hydrodynamic radius, rh, of the particle: 
 
    
  
     
    (5-4) 
 
where k = Boltzmann’s constant 
T = temperature 
 = viscosity of the solvent 
 
For samples with a broad size distribution of spheres, the correlation function must be 
solved for each size within the distribution.  Therefore, the equation for the correlation 
function becomes: 
 
 ( )   ∫ ( )         (5-5) 
 
 
The solution to this equation is quite complex; however, the Non-negatively constrained 
Least Squares (NNLS) algorithm was developed and is utilized for multimodal size 
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where d = diameter 
G(d) = weighing factor 
 
The width of the distribution is described by the relative variance. 
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The size distribution is measured as average diameters that are weighed by the intensity, 
number, volume, or surface area of the sample.  Each of these diameters provides a 
means of describing the size distribution of the sample, and therefore the reported value 
depends on the particular application.  The number average provides information about 
the relative number of particles of a particular size in a polydisperse solution.  This is 
often used to describe liposomes solutions that have a majority population of SUVs 








5.2.2  Results 
 
Liposome formulations were prepared as described in Section 5.1 and the size 
distribution was measured by dynamic light scattering (ZetaPALS, Brookhaven 
Instruments Co., Holtsville, NY) at the National Institute of Standards and Technology 
(NIST).   The size distribution was measured for unhomogenized liposome formulation, 
formulation homogenized for a single cycle, and formulation homogenized for two 
cycles.  The liposome formulation was analyzed with the following conditions:  
temperature = 25
o
C, viscosity = 0.89 cp, fluid refractive index = 1.33, and angle = 90
o
.  
The liposomes were modeled as a thin shell with the Mie scattering coefficient 
independent of the shell’s refractive index.  Given the relative size of the liposome lipid 
bilayer in relation to the diameter of the liposomes and the same aqueous solution 
surrounding and within the liposomes, the thin shell assumption is valid.  Size analysis 
was performed using ZetaPlus Particle Sizing Software version 3.93 (Brookhaven 
Instruments Corp., Holtsville, NY).  All runs were one minute in duration and repeated 
five times. 
 
The unhomogenized liposome formulation contained a large range of liposome sizes, 
with aggregates visually evident in the formulation.  Given the increased scattering 
intensity of large particles, the polydispersity of the unhomogenized sample could not be 
quantified.  The correlation function is shown in Figure 5-6.  When compared to the 
homogenized samples presented later in this section, the uncertainty in the exponential 
decay as delay time is increased along with the equilibrium point above the baseline 








Figure 5-7.  The correlation function, C(), generated with dynamic light scattering for 
the unhomogenized liposome formulation as a function of delay time, .  Note the non-
uniform slope within the exponential decay and high baseline equilibrium point.   
 
Following a single pass through the homogenizer at 20,000 psi, aggregation within the 
liposome formulation decreased significantly.  The formulation transformed into a more 
uniform solution that remained in suspension when allowed time to settle.  These visual 
changes were confirmed when analyzed with DLS.  As shown in Figure 5-7, the 
correlation function has a much smoother exponential decay as the delay time is 
increased.  Additionally, the baseline equilibrium is established closer to zero.  Given the 
higher quality of scattering data, number weighted MSD with NNLS analysis was 









Figure 5-8.  The correlation function, C(), generated with dynamic light scattering as a 
function of delay time, , following single cycle homogenization of the liposome 
formulation at 20,000 psi. 
 
A more detailed analysis of the MSD is provided in Table 5-1. 
 
Table 5-1.  Number-weighted size distribution of the single cycle homogenized liposome 
formulation. 










The one cycle homogenization resulted in a mean diameter of 98.5 nm with a relative 







Following a second pass through the homogenizer at 20,000 psi, aggregation within the 
liposome formulation decreased slightly.  As shown in Figure 5-8, the correlation 
function exhibits a similar exponential decay as the delay time is increased.  The baseline 
equilibrium is less noisy when compared to the single pass.   
 
 
Figure 5-9.  The correlation function, C(), generated with dynamic light scattering as a 
function of delay time, , following double cycle homogenization of the liposome 
formulation at 20,000 psi. 
 












Table 5-2.  Number-weighted size distribution of the two cycle homogenized liposome 
formulation. 











The two cycle homogenization resulted in a mean diameter of 111.5 nm with a relative 
variance of 0.113.   
 
5.3  BCH Loading Efficiency 
 
Analysis of the liposome formulation following preparation via the thin film hydration 
method was performed using ICP-MS to measure the BCH loading efficiency.  The 
protocol for 
10
B analysis in the liposome formulation closely followed the description in 
Chapter 6.  The loading efficiency at two different BCH concentrations was tested, one 
with 5.5 mg of BCH added to the lipid solution (21.3 g 
10
B/mL) and the second with 
11.0 mg of BCH added (42.6 g 
10
B/mL).  The concentration of BCH within the 
liposome formulation as detected by ICP-MS was 6.3 and 16.8 g 
10
B/mL, respectively.  
Therefore, the loading efficiency for the lower concentration liposome formulation is 
29.7% and increases to 39.3% for the higher concentration.  The value of 29.7% is 





formulation.[44]  After selecting the 5.5 mg BCH liposomes for the BNCT irradiations, 
the loading efficiency was repeated in triplicate and yielded an efficiency of                 
32.9 + 2.7 %. 
 
To quantify the importance of agitating the liposomes with glass beads during hydration 
and homogenization, as described in Section 5.1, the impact of each process on BCH 
loading efficiency was investigated.  
10
B concentrations in liposome formulations without 
bead agitation, with bead agitation, and with bead agitation followed by homogenization 
were studied.  The results of each sample are summarized in Table 5-3.  The results 
shown are based on preliminary studies to evaluate the optimal parameters for BCH 
loading.  They are not mean to provide quantitative analysis, and thus no values for 
uncertainty are provided. 
 
Table 5-3.  Loading efficiency of BCH as a function of various preparation schemes. 
Liposome Formulation Sample Preparation Loading Efficiency (%) 
No glass beads  7 
With glass beads  22 
With glass beads and homogenization 30 
 
 
The increase in loading efficiency when glass beads are used to agitate the lipids during 
thin film hydration is significant.  Glass beads increased the loading efficiency by a factor 
of three, likely due to the strong hydrophobic nature of BCH that is dried on the walls of 





note than many glass beads are made of borosilicate glass, a potential source of non-BCH 
boron.  In order to verify that the increase in boron concentration could be attributed to 
the BCH agitation from the glass wall rather than contamination from the borosilicate 
glass, the extraction of boron from glass beads was analyzed.  Glass beads were placed in 
DPBS solution for 24 hours at room temperature, DPBS solution for 72 hours at room 
temperature, 1% nitric acid for 24 hours at room temperature, and 1% nitric acid for 72 
hours at room temperature.  Following each test, 1 mL of solution was removed and 
analyzed with ICP-MS.  In each sample, the concentration of boron was below the limit 





Chapter 6:  Cellular Drug Delivery of BCH 
 
 
6.1  Cell Culture 
 
Human cancerous prostate PC-3 cells (NCI-PBCF-CRL1435, American Type Culture 
Collection (ATCC), Manassas, VA) were grown in F-12K medium (Kaighn’s 
modification of Ham’s F12 medium supplemented with 2 mM L-glutamine, 1.5 g/L 
sodium bicarbonate) (30-2004, ATCC, Manassas, VA) and 10% (v/v) fetal bovine serum 
(FBS) (30-2020, ATCC, Manassas, VA) at 37
o
C in 5% CO2 in air.  The PC-3 cell line 
was originally derived from the bone marrow of a 62 year old Caucasian male with grade 
IV prostatic adenocarcinoma.[87]  Cells were grown in Corning

 cell culture flasks with 
vented caps (Sigma-Aldrich, St. Louis, MO).  When growing the cells, growth medium 
was replaced 2-3 times per week and the cells were subcultured when confluency reached 








Figure 6-1.  PC-3 cells under microscope at various time points with an initial plating 






PC-3 cells were subcultured according to the following protocol (volumes given for T-75 
flask):  growth medium was aspirated from the cell flask and cell monolayers were 
washed with 5 mL of Dulbecco’s phosphate-buffered saline (DPBS) modified without 
calcium chloride and without magnesium chloride (30-2200, ATCC, Manassas, VA), 3 
mL of 0.25% (w/v) trypsin-0.53 mM EDTA (30-2101, ATCC, Manassas, VA) was added 
to the flask and incubated for 10 minutes, cell detachment was confirmed under 
microscope prior to harvesting, trypsin was neutralized with 8 mL growth medium and 
pipetted up and down for 20 cycles.  Approximately 2.5 x 10
6 
cells were plated in a new 
flask and a total volume of 15 mL growth medium was added to the flask. 
 
The growth profile for PC-3 cells is shown in Figure 6-2.  The population doubling time 







Figure 6-2.  Growth profile for PC-3 cells (ATCC). 
 
6.2  Cell Viability 
 
The viability of PC-3 cells after incubation with the BCH-containing liposome 
formulation was quantified with neutral red, MTS, and LDH cytotoxicity assays.  Each 
assay was analyzed as a means of understanding the disruption of cellular processes for 
comparison with cells exposed to the BCH-containing liposomes followed by irradiation 
in a thermal neutron field.   
 
6.2.1  Neutral Red 
 
The neutral red assay system provides a means of measuring living cells through the 







Figure 6-3.  Chemical structure of neutral red. 
 
The neutral red method relies on the active transport and incorporation of neutral red dye 
into the lysosomes by viable cells [89] and has been successfully implemented as a means 
of testing cytotoxicity in a variety of cell cultures.[90]   
 
Prior to performing the neutral red assay, a cell density-dependent uptake curve was 
established to determine the proper cell seeding density.  The curve was established by 
plating 0, 1000, 5000, 10000, 50000, and 100000 cells in 100 L of growth media.  Cells 
were incubated for 24 hours prior to the Neutral Red Based in vitro Toxicology Assay Kit 
(TOX-4, Sigma-Aldrich, St. Louis, MO).  Following the incubation phase, 10 L of 
0.33% Neutral Red Solution (N-2889) was added to each well and the plate was returned 
to the incubator for 2 hours.  The media and dye were removed from the wells and the 
cells rinsed twice with 200 L of PBS.  Following the rinse, 50 L of Neutral Red Assay 
Solubilization Solution (N-4395) was added to the wells and kept at room temperature for 
10 minutes.  The absorbance was measured at 540 nm using a SpectraMax 190 
microplate reader with SoftMax Pro 5 GxP software (Molecular Devices Corporation, 








Figure 6-4.  Neutral Red uptake curve showing dye concentration in the lysosomes as a 
function of cells plated.  Error bars represent + 1 SD. 
 
 
For the cell cytotoxicity studies, 5000 cells were plated and incubated for 48 hours prior 
to the addition of liposomes.  At the conclusion of the 48 hour incubation period, two 
different amounts of liposome formulation were added to the wells.  For the 1x 
concentration, 7.7 L of liposome formulation was added to the 200 L of cell media in 
the wells.  For the 2x concentration, 15.4 L of liposome formulation was added to the 
200 L of cell media in the wells. 
 
In order to determine the cytotoxicity of the liposome formulation, 96-well plates were 
loaded with the following sample sets:  (1) cell media, (2) cell media and 1x liposome 
formulation, (3) cell media and 2x liposome formulation, (4) cell media and cells 
(control), (5) cell media, cells, and 1x liposome formulation incubated for 24 hours, (6) 





















cells, and 1x liposome formulation incubated for 48 hours, and (8) cell media, cells, and 
2x liposome formulation incubated for 48  hours. 
 
 
Figure 6-5.  Neutral Red assay results for PC-3 cells grown with and without liposomes.  
Data points represent the average of n=7 and statistical significance was determined using 
Analysis of Variance (ANOVA) and Dunnett’s posttest.  Analysis was performed using 
GraphPad Prism software (GraphPad, Inc. La Jolla, CA).  * denotes p <0.05.  
 
 
As seen in Figure 6-5, the addition of BCH-containing liposomes has no statistically 
significant impact on PC-3 cells regarding active uptake of neutral red dye into the 
lysosomes for the 1x liposome concentration experiments.  There is a slight decrease in 
the average cell lysosome concentration capacity of the cells incubated with 2x liposome 
formulation for 24 hours.  The 2x liposome formulation sample set was not performed in 
the post-irradiation colony formation assay studies presented in Chapter 7 in order to 
minimize the interruption of cell behavior unrelated to the thermal neutron capture 








































AQueous One Solution Assay (Promega Corp., Madison, WI) is a 
colorimetric method for measuring the number of viable cells in proliferation within a 
cell culture.[91]  Cell viability within the cell culture is determined by the detection of 
formazan.  Specifically, a tetrazolium compound [3-(4,5-dimethylthaizol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], MTS, is bioreduced by the 
cells and converted into formazan.  A majority of this bioreduction is accomplished by 
nicotinamide adenine dinucleotide phosphate (NADPH) or nicotinamide adenine 
dinucleotide dehydrogenase (NADH) products from dehydrogenase enzymes within 
metabolically active cells.[92]   
 
 
Figure 6-6.  Bioreduction of MTS resulting in the formation of formazan. 
 
Prior to performing the MTS assay, an MTS bioreduction curve was established to 
determine the proper cell seeding density.  The curve was established by plating 0, 1000, 
5000, 10000, 50000, and 100000 cells in 100 L of growth media.  Cells were incubated 









AQueous One Solution Reagent was added to each well and incubated for 
one and two hour increments.  The absorbance was measured at 490 nm using a 
SpectraMax 190 microplate reader with SoftMax Pro 5 GxP software (Molecular 
Devices, Sunnyvale, CA).[93, 94]  The results are shown in Figure 6-7.   
 
 
Figure 6-7.  MTS response curve showing bioreduction as a function of cells plated. Error 
bars represent + 1 SD. 
 
 
In order to determine the cytotoxicity of the liposome formulation, 96-well plates were 
loaded with the following sample sets:  (1) cell media, (2) cell media and 1x liposome 
formulation, (3) cell media and 2x liposome formulation, (4) cell media and cells 
(control), (5) cell media, cells, and 1x liposome formulation incubated for 24 hours, (6) 
cell media, cells, and 2x liposome formulation incubated for 24 hours, (7) cell media, 
cells, and 1x liposome formulation incubated for 48 hours, and (8) cell media, cells, and 
2x liposome formulation incubated for 48  hours.  A two hour incubation period was used  






























Figure 6-8.  MTS assay results for PC-3 cells grown with and without liposomes.  Data 
points represent the average of n=7 and statistical significance was determined using 
ANOVA and Bonferroni’s posttest.  Analysis was performed using GraphPad Prism 
software (GraphPad, Inc. La Jolla, CA).  * denotes p <0.05 and ** p <0.001. 
 
 
As shown in Figure 6-8, the liposome formulation appears to increase the metabolic 
activity within the PC-3 cells.  The 2x concentration of lipsome formulation increases the 
metabolic activity in both the 24 and 48 hour incubation experiments with respect to the 
1x lipsome forumation samples.  In addition to this, metabolic activity decreases when 
the PC-3 cells are incubated with the BCH-containing liposomes for a 48 hour period at 
both concentrations.  This observation contributed to the selection of the 24 hour 
incubation protocol for cell survial assays following irradiation with thermal neutrons.  
When determining the efficacy of BCH for the treatment of prostate cancer cells as part 
of a BNCT regime, isolating the targeted impact of the boron capture reaction from other 









































 Non-radioactive Cytotoxicity Assay is a colorimetric method for 
measuring cell lysis within cell culture.  The assay measures cell lysis through the 
detection of lactate dehydrogenase [68] in cell media.  LDH is a stable cytosolic enzyme 
that is released from the cell when lysis occurs.  Once released into the cell media, the 
conversion of a tetrazolium salt into a red formazan product results in a quantifiable 
measure of cell lysis within a cell culture well.[95-97]   
 
Prior to performing the LDH assay, an LDH release curve was established to determine 
the proper cell seeding density.  The curve was established by plating 0, 1000, 5000, 
10000, 50000, and 100000 cells in 100 L of growth media in a round bottom plate.  
Cells were incubated for 24 hours prior to performing the assay.  Following the 
incubation period, 10 L of Lysis Solution was added to the bottom four wells of each 
sample and incubated for one hour.  The plate was centrifuged at 400 rpm for four 
minutes.  In a separate flat bottom 96-well plate, 50 mL of Substrate Mix was added to 
each well.  50 mL of the supernatant from each well of the round bottom flask was then 
added to the 50 mL of Substrate Mix.  The sample was covered with aluminum foil and 
left at room temperature for 30 minutes.  50 mL of Stop Solution was added to each well 
and left at room temperature for 10 minutes.  The absorbance was measured at 490 nm 
using a SpectraMax 190 microplate reader with SoftMax Pro 5 GxP software (Molecular 







Figure 6-9.  LDH response curve showing spontaneous LDH release as a function of cells 
plated.  Error bars represent + 1 SD. 
 
 
In order to determine the cytotoxicity of the liposome formulation, 96-well plates were 
loaded with the following sample sets:  (1) cell media, (2) cell media and 1x liposome 
formulation, (3) cell media and 2x liposome formulation, (4) cell media and cells 
(control), (5) cell media, cells, and 1x liposome formulation incubated for 24 hours, (6) 
cell media, cells, and 2x liposome formulation incubated for 24 hours, (7) cell media, 
cells, and 1x liposome formulation incubated for 48 hours, and (8) cell media, cells, and 
































Figure 6-10. LDH assay results for PC-3 cells grown with and without liposomes. Data 
points represent the average of n=3 and statistical significance was determined using 
Analysis of Variance (ANOVA) and Dunnett’s posttest.  Analysis was performed using 
GraphPad Prism software (GraphPad, Inc. La Jolla, CA).  No data sets were statistically 
significant compared to the control.  
 
 




6.3  BCH Uptake Analysis 
 
 
6.3.1  High-Performance Liquid Chromatography 
 
 
High-performance liquid chromatography (HPLC) is an analytical chemistry technique 































A small volume of sample is mixed with the mobile phase (solvent) and pumped through 
a chromatography column (stationary phase).  As the solvent passes through the 
stationary phase, the components in the sample separate as they experience varying 
degrees of dispersive, dipole, and ionic interaction with the stationary phase.  The 
different degrees of interaction within the stationary phase result in a characteristic 
retention time within the column as a function of the chemical properties of the 
components within the mixture.  As the separated components elute from the stationary 
phase, ultraviolet detection is used to quantify each component.  A schematic of an HPLC 




Figure 6-11.  Schematic of high-performance liquid chromatography. 
 
 
There are a number of different types of HPLC separation, such as normal phase, reverse 
phase, non-aqueous, ion-exchange, size exclusion, etc.  Due to the hydrophobicity of the 
BCH molecule, non-aqueous reverse phase (NARP) chromatography was chosen to 





hydrophobic medium.  HPLC has been used previously as a method for detecting 
cholesterol and cholesteryl esters.[98-101] 
 
HPLC was used to analyze the BCH within the cell samples in a method adapted from 
previous work by Dr. Sidwell.[102]  Cell pellets were dried for 15 hours using a 
SpeedVac on medium heat.  A solution of 1:1 (v:v) methanol:isopropanol (HPLC grade, 
Sigma-Adlrich, St. Louis, MO) was prepared and 1 mL added to the dried cells.  The 
sample was vortexed for 10 seconds and the cells were ruptured to release the BCH using 
a probe sonicator.  Cells were then rotated at 120 rpm for 30 minutes.  Following this 
rotation, cells were centrifuged at 800 rcf for 10 minutes.  For HPLC analysis, 50 L of 
supernatant was injected in the column.  HPLC was performed using a HP Agilent Series 
1100 unit equipped with a column heater, UV-Vis photodiode array detector, 7725i 
manual injector, Agilent ZORBAX C-18 5 m 150 x 4.6 mm analytical column, and 
Agilent ZORBAX C-18 5 m 12.5 x 4.6 mm guard column.  All samples were eluted 
isocratically at a flow rate of 0.5 mL/min and a column temperature of 40
o
C using a 
mobile phase of 1:1 (v:v) methanol:isopropanol and detected by UV absorbance at the 
max of BCH (202 nm).  The conditions yielded a column back pressure of approximately 
25 psi and a retention time for BCH of approximately 13.5 minutes.  All sample injection 
volumes were 50 L.  
 
As reported previously, BCH uptake within a cell sample can be quantified using 
HPLC.[43, 102]  The calibration curve for BCH detection was established by dissolving 





mL of 1:1 (v/v) methanol:isopropanol mobile phase solution.  A second standard solution 
was then prepared by diluting 10 mL of the first standard solution to a total volume of 50 
mL with 1:1 (v/v) methanol:isopropanol mobile phase solution.   The volume of standard 
solution injected onto the column was varied from 10-100 L.  This resulted in a 
calibration curve for BCH concentrations ranging from 0.8-40 g/mL. 
 
 
Figure 6-12.  Chemical structures of the compounds within the HPLC standard solution 
(a) cholesteryl oleate, (b) cholesteryl heptadecanoate, (c) cholesterol, and (d) BCH. 
 
As shown in Figure 6-13, a key advantage to using HPLC as a detection method for 
boron uptake in cells is that the intact BCH molecule can be measured.  This allows a 
differentiation between boron delivered in the form of BCH and native boron within the 
cell or from contamination of the sample.  As previously reported, BCH can successfully 
be separated from similarly sized compounds within the cell.[102]  The HPLC separation 





within this separation system is approximately 13.5 minutes.  Analysis of PC-3 cells 
without the addition of BCH-loaded liposomes confirmed that the 13.5 minute peak 
found in the separation spectrum is unique to BCH. 
 
Figure 6-13.  HPLC separation spectrum of the standard solution illustrating the 
separation capabilities of the non-aqueous reverse phase setup. 
 
A more thorough description of the separation parameters, including retention factors and 
plate numbers, is provided by Dr. Sidwell.[102]   
 
From the analysis of the standard solutions, the calibration curve for BCH detection by 
HPLC with peak area of the 13.5 minute peak directly proportional to the quantity of 





































relatively linear across a large range of concentrations, the lower end of the range was 
used to quantify BCH presence in cell samples in order to minimize uncertainty. 
 
 
Figure 6-14.  Calibration curve for BCH detection using HPLC.  Data points represent the 
average of n=3 with a RSD <5%. 
 
BCH uptake by PC-3 cells was investigated using the following protocol.  PC-3 cells 
were subcultered four times and 5x10
6
 cells were seeded in a T-150 flask.  The cells were 
incubated for 48 hours prior to addition of the liposome formulation.  The 48 hours 
incubation time was selected to ensure that the PC-3 were within the logarithmic growth 
phase when exposed to the BCH-containing liposomes.  Following the initial incbuation 
phase, the growth medium was aspirated from the flasks and the necessary volume of 
liposome formulation was added to the flask.  Growth medium was added to the flasks to 
bring the final volume to 26 mL.  After the incubation with BCH, the liposome 
formulation and growth medium were aspirated from the flask and the cells were washed 
three times with DPBS.  Previous studies investigating the adherence of BCH on the cell 
y = 947.82x - 7.7376 





























exterior reported that washing with DPBS is sufficient to remove non-specific BCH that 
had not undergone cellular endocytosis.[43]  Cells were then trypsinized and pelleted for 
analysis.  Cell pellets were stored at 4
o
C until analyzed. 
 
 
6.3.2  Inductively Coupled Plasma-Mass Spectrometry 
 
 
Inductively coupled plasma-mass spectrometry (ICP-MS) is an analytical technique for 
determining elemental composition of a sample; and its efficacy in detecting low 
concentrations of boron has been established.[103-105]  The use of ICP-MS in 
quantifying boron in a variety of biological samples [106-108], as well as the specific 
detection of boron from BCH in cell culture has been reported[44].  In short, ICP-MS 
analysis involves the use of a high-temperature plasma discharge to generate positively 
charged ions within a sample.  Following the generation of positive ions, mass 
spectrometry is utilized to detect the ions and determine the elemental composition of the 
injected sample.  The first process for ICP-MS analysis requires the generation of a fine 
aerosol using a nebulizer.  The liquid sample is injected into the nebulizer as the 
pneumatic action of a flow gas breaks the sample into small droplets.  Following 
formation of the droplets within the nebulizer, large droplets (> 10 m) are filtered out in 
the spray chamber.  Large droplets must be filtered out at this stage due to the 
inefficiency in dissociating them in the plasma discharge.  After passing through the 
spray chamber, the small droplets are transported to the sample injector of the plasma 
torch.  Within the plasma torch, a plasma discharge is created as argon gas flows through 





field is created that accelerates electrons formed when a high-voltage spark is applied to 
the argon gas.  These newly formed electrons are accelerated in the magnetic field and 
collide with other argon atoms, generating a cascade of electrons.  The collection of 
argon atoms, argon ions, and electrons form the inductively coupled plasma discharge.  A 
third carrier gas then flows through the plasma discharge, introducing the aerosolized 
sample.  As the sample droplets pass through the plasma, they undergo a series of 
changes in the preheating, radiation, and analytical zones.  In the preheating zone, the 
droplet undergoes desolvation and becomes a very small, solid particle.  Continuing 
through the plasma, the solid is converted into a gaseous form and then a ground state 
atom.  At this point, the ground state atoms collide with the electrons in the plasma 
discharge and are converted into ions.  The ions generated in the plasma then enter the 
interface region for transport to the mass spectrometer.  In the interface region, ions pass 
through the sampler and skimmer cones before entering the ion optics.  The ion optics 
function to transport the analyte ions to the mass spectrometer while filtering out as much 
of the matrix components as possible.  This is accomplished by electrostatically 
controlled lens components which discriminate matrix ions and preferentially direct 
analyte ions to the mass spectrometer.  Ions are separated by mass-to-charge ratio by the 
quadrupole mass filter.  The quadrupole mass filter consists of four cylindrical rods, one 
pair imparted with a direct current (DC) field and the other pair with a RF.  Working in 
concert, these four rods steer the ions of a particular mass-to-charge ratio to the detector.  
Manipulating the DC-RF voltage within the quadrupole mass filter permits the detection 
of a range of mass-to-charge ratios.  After emerging from the mass analyzer, the ions are 





ion flowing from the quadrupole mass filter is directed toward and strikes a dynode.  
Secondary electrons are liberated from the dynode and accelerated to the subsequent 
dynode, where more electrons are liberated.  This process repeats itself in cascading 
fashion until the electrons are collected on the anode.  The pulse created from the 
electrons at the anode is detected by a preamplifier and sent to a digital discriminator and 
counting circuitry.  A schematic of ICP-MS is provided in Figure 6-15.  Further 
discussion of ICP-MS can be found in a tutorial by Dr. Thomas.[109] 
 
 
Figure 6-15.  Schematic of ICP-MS. 
 
 
The first step in detecting boron with ICP-MS is to establish a protocol for solubilizing 




B, and natural boron standards were mixed in a series of nitric acid dilutions to 
determine the optimal method of introducing the boron into the sample chamber.  
Because the goal of BNCT is the targeted intracellular delivery of 
10





were optimized for this measurement.  Figure 6-16 shows the 
10
B standard curve 
generated using the boron standard in nitric acid. 
 
 
Figure 6-16.  Standard curve for 
10
B detection using ICP-MS.  Data points represent the 
average of n=10 with a RSD <2% for all points above the LoQ. 
 
The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) were 
calculated to be 0.710, 0.976, and 1.626 ppb, respectively.  These limits correspond with 
other published results.[110] 
 
Upon successfully measuring 
10
B and generating a linear standard curve, a method was 
established for analyzing 
10
B in m-carborane (Sigma-Aldrich, St. Louis, MO) and BCH.  
Combinations of nitric acid concentration (10, 40, and 70%) with incubation times (4, 8, 
24, 48, and 72 hours) were investigated.  
10
B in m-carborane was detected using the 70% 
nitric acid concentration and incubation times of at least 8 hours.  On the other hand, the 
y = 0.9963x - 0.3234 






















BCH remained undigested even after 72 hours of incubation in 70% nitric acid.  In order 
to facilitate the digestion of the  BCH, a heating step was added to the method.  Digestion 
temperatures of 50, 75, 110, and 150
o
C were tested.  At this point, a few additional 
variables were considered.  Initially, 15mL Falcon polypropylene tubes were utilized in 
the digestion procedures.  However, the structural integrity of the caps could not 
withstand the 150
o
C heating step.  Without a reliable cap to prevent sample loss during 
the digestion, this method was not viable.  The next step was to perform the heated 
digestions in Teflon tubes.  While the Teflon tubes were capable of withstanding the 
temperatures during the digestion, the pressure buildup within the tube dislodged the 
caps.  Absent a means of securing the Teflon caps, the next test was performed with the 
digestion in Parr Acid Digestion Vessels.  Combining the ntiric acid with a heated 
digestion in the Parr Acid Digestion Vessels provided an adequate methodology for the 
detection of 
10
B in both the m-carborane and BCH samples.[111] 
 
        
Figure 6-17.  Schematic and image of Parr Acid Digestion Vessel used in the digestion of 






Once the detection of 
10
B in BCH with ICP-MS was established, the next step was to 
develop a protocol for digesting the PC-3 cells.  This would allow the establishment of a 
background 
10
B level within the human prostate cancer cells.  In addition to dissolving 
the 
10
B, the addition of biological material required another digestion component.  A 30% 





 cells.  The cell pellets were also spike with 
10
B standard, m-carborane, 
and BCH to test the ability and efficiency of boron detection in a matrix of biological 
material.  
 
There are two key parameters that must be accounted for when digesting and analyzing 
the PC-3 
10
B uptake.  First, boron tends to form micro-precipitates in the presence of 
highly concentrated nitric acid.[104]  ICP-MS is unable to detect such precipitates, 
yielding an artificially low 
10
B uptake in the sample.  Therefore, it is recommended that 
the final nitric acid concentration in the ICP-MS injection sample be kept below 2%.  
Second, the final dilution of the sample must be kept sufficiently concentrated for the 
10
B 
concentration to remain within the linear range of the 
10
B calibration curve and above the 
lower limit of quantitation.  With these two competing parameters in mind, a broad 
variety of testing conditions were investigated.  After analyzing the various conditions, 
the optimum procedure was determined to include: (1) transferring the cell pellet to the 
Teflon insert of the Parr Acid digestion vessel (Parr Instrument Co., Moline, IL) with 0.1 
mL of Dulbecco’s phosphate-buffered saline (D-PBS, Invitrogen Corp., Carlsbad, CA), 
0.29 mL of 70% nitric acid (Optima Ultrapure Grade, Fisher Scientific, Pittsburgh, PA), 





Louis, MO), and 0.01 mL of the 
103
Rh recovery standard (10 mg/mL, SPEX CertiPrep, 
Methuchen, NJ), (2) capping the digestion vessel and allowing 24 hours of room 
temperature digestion, (3) transferring the digestion vessel to a muffle furnace (Fisher 
Isotemp Muffle Furnace, Fisher Scientific, Pittsburgh, PA) for a 8 hour heated digestion 
at 150
o
C, (4) transferring the digestion solution to a 15 mL conical polypropylene tube 
(B-D Falcon, Franklin Lakes, NJ) and diluting to a final volume of 10 mL with Milli-Q 
ultrapure water (18.2 M-cm, Milli-Q Ultrapure Water System, Millipore Corp., 
Billerica, MA).  Samples were then analyzed using ICP-MS (X-Series II ICP-MS 
System, ThermoScientific, Waltham, MA) equipped with an autosampler (Cetac ASX520 
Autosampler, Omaha, NE) flowing 99.997% pure high-pressure liquid argon as the 



















Table 6-1.  Instrument settings for ICP-MS analysis of the BCH uptake in PC-3 cells. 
Instrument Model: Thermo X-Series II 
Nebulizer Concentric 
Spray chamber Conical 
Torch injector Quartz (1.5 mm) 
Forward power 1400 W 






Sampler 1.0 mm 
Skimmer 0.9 mm 










Scanning mode Peak jumping 
Acquisition time  4 s 
Replicates 3 
Sweeps 100 
Dwell time 10 ms 
Sample uptake rate (mL/min) 1.0 





The instrument was calibrated with external standards of the appropriate metal standard 
in 2% nitric acid.  The sample probe was washed with a constant flow of 2% nitric acid 
between measurements.  Quantitative analysis was obtained by reference to the slope of 
the calibration curve (counts per second/ng per liter), as well as an internal standard. 
 
BCH uptake by PC-3 cells was investigated using the following protocol.  PC-3 cells 
were subcultered four times and cells were seeded in a T-150 flask.  The cells were 
incubated for 48 hours prior to addition of the liposome formulation.  The 48 hours 
incubation time was selected to ensure that the PC-3 were within the logarithmic growth 
phase when exposed to the BCH-containing liposomes.  Following the initial incbuation 
phase, the growth medium was aspirated from the flasks and the necessary volume of 
liposome formulation was added to the flask.  Growth medium was added to the flasks to 
bring the final volume to 26 mL.  After incubation with BCH, the liposome formulation 
and growth medium were aspirated from the flask and the cells were washed three times 
with DPBS.  Cells were then trypsinized and pelleted for analysis.  Cell pellets were 
stored at 4
o
C until analyzed.   
 
6.4  BCH Uptake Results 
 
The uptake of BCH in PC-3 cells was investigated using HPLC and ICP-MS, as 
described in Sections 6.3.  The primary goal for delivery of BCH is to load sufficient 
boron (20-35 g/g cell) into the cells while minimizing toxicity.  Toxicity effects of BCH 





medium was chosen.[44, 112]  Cytotoxicity of the PC-3 cells was investigated and 
discussed in Section 6.2.  Three main variables that were investigated for cellular uptake 
of BCH are incubation time, BCH concentration in the growth medium, and cell plating 
density.   
 
It is important to note that the results shown in Figures 6-18 through 6-21 are based on 
preliminary studies to narrow the broad range of potential drug delivery parameters.  
They are not meant to provide quantitative analysis, and thus no values for uncertainty 
are provided.  The trends observed factored into the optimization of the drug delivery 
parameters.  Once the drug delivery protocol was established, quantification of BCH 
uptake in the PC-3 cells was analyzed with associated uncertainty discussed at the 
conclusion of this chapter.  In addition to this, the BCH compound used in this research 




B are 19.9 and 80.1%, respectively.  When used in a clinical setting, boron-containing 
BNCT compounds are synthesized with enriched 
10
B.  Therefore, for BNCT analysis of 








The initial studies performed to identify the relationship between BCH uptake and 
incubation time were performed using 1 mL of liposome formulation (1.3 g boron/mL 





 and grown for 48 hours prior to the addition of the BCH-





to harvesting of the cell samples for HPLC analysis as described in Section 6.3.  In the 





 and grown for 48 hours prior to the addition of the BCH-containing liposome 
formulation.  The cells were then incubated for 6, 16, and 24 hours prior to harvesting of 
the cell samples for ICP-MS analysis as described in Section 6.4.  The results of the 
boron uptake as a function of incubation time are shown in Figure 6-18 and all uptake 




B) per g of cell (10
9
 cells = 1 g). 
 
        
Figure 6-18.  Boron uptake in PC-3 cells as a function of incubation time with ICP-MS as 




 and grown for 48 hours prior to 
the addition of the liposome formulation.  Cells were incubated with BCH for 6-24 hours 





per g of cell (10
9
 cells = 1 g).  
 
 
BCH uptake for the 4 and 24 hour incubation times as measured with HPLC were 8.6 



























The general trend in boron uptake as a function of incubation time is evident in both 
analyses.  However, there is a significant decrease in boron uptake for the samples 
analyzed with ICP-MS.  When comparing the uptake after 24 hours, the HPLC analysis 
yielded a value of 34.2 g/g cell compared to 10.2 g/g cell for the ICP-MS analysis.  
This can be explained by the difference in cell plating density of the two experiments.  
Although the growth characteristics of the PC-3 cells did not appear to vary significantly 






, there is a clear 
dependence for BCH uptake.  To further investigate this matter, the experiment with ICP-




 plating density as in the HPLC 
experiments.  The results of this are shown in Figure 6-19.   
 
 
Figure 6-19.  Boron uptake in PC-3 cells as a function of initial cell plating density with 







grown for 48 hours prior to the addition of the liposome formulation.  Cells were 
incubated with BCH for 24 hours and harvested for analysis.  Uptake results are reported 
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By increasing the plating density from 2x10
6
 total cells in a T-150 flask to 5x10
6
 total 
cells, the boron uptake increased from 10.2 to 36.0 g/g cell.  Because the boron  uptake 
is corrected to cell number in the final calculation, this change is not simply explained by 
comparing the raw number of cells within the flask.  The cell density within a in vitro 
growth environment plays a vital role in biological processes.  Secretion of growth 
factors, cell-cell communication, enzymatic acticity, and protein expression, are 
examples of cellular behavior that are impacted by plating density.  Variations in cell 
plating density have been shown to impact drug delivery in a number of cellular systems 
and must be accounted for when analyzing drug uptake and toxicology.[113-115]     
Further investigation into the mechanisms of boron uptake in relation to cell signalling 
and cell-cell contact interaction is beyond the scope of this research, however, warrants 
attention as a future extention. 
 
When the cell plating densities was kept constant between the two experimental methods, 
boron uptake for PC-3 cells incubated for 24 hours in 1.3 g boron/mL growth medium 
was measured with HPLC at 34.2 g/g cell and 36.0 g/g cell with ICP-MS.   
 
The dependence of BCH uptake on the concentration of boron within the growth medium 
was also studied.  For this set of experiments, cell cultures were prepared as described 
above and 1 or 2 mL of liposome formulation was added, yielding boron concentrations 
of 1.3 and 2.6 g/mL in growth medium.  The cells were incubated with the liposomes 





experiments, cell cultures were prepared and 0.5, 1.0, and 1.5 mL of liposome 
formulation yeilding boron concentrations of 0.6, 1.3, and 1.9 g/mL of growth medium.  
The results of the ICP-MS boron uptake as a function of boron concentration within the 
growth medium are shown in Figure 6-20. 
 
 
Figure 6-20.  Boron uptake in PC-3 cells as a function of liposome concentration within 





 and grown for 48 hours prior to the addition of the liposome formulation.  Cells 
were incubated with BCH for 24 hours and harvested for analysis.  Uptake results are 




B) per g of cell (10
9
 cells = 1 g).  
 
HPLC analysis of BCH uptake for the 1 and 2 mL liposome formulations yielded an 
uptake of 39.8 g/g cell and 71.2 g/g cell, respectively. 
 
The general trend in boron uptake as a function of boron concentration in the growth 
medium is evident in both analyses.  As discussed previuosly, the quantitative difference 
in uptake measured with HPLC and ICP-MS is attributed to the difference cell seeding 





























The dependence of BCH uptake on extended  incubation times at the higher seeding 
density was then studied with ICP-MS.  For this set of experiments, cell cultures were 




 and the 
incubation time following addition of the BCH-containing liposomes was observed at 24, 
36, and 48 hours following the addition of 1.3 mg boron/ mL growth medium.  The 
results of the boron uptake as a function of incubation time are shown in Figure 6-21. 
 
 
Figure 6-21.  Boron uptake in PC-3 cells as a function of incubation time with ICP-MS as 




 and grown for 48 hours prior to 
the addition of the liposome formulation.  Cells were incubated with BCH for 24, 36, and 





B) per g of cell (10
9
 cells = 1 g).  
 
Unlike previous experiments focusing on the boron uptake relationship as a function of 
incubation time for 0-24 hours, there appears to be a plateau forming as the cells are 





























relationship from 0-24 hours is replaced with a levelling off, and possibly slight decline, 
in boron uptake for the longer incubation times.  While this observation is interesting in 
its own right, it is important to note another key observation during this set of 
experiments.  The MTS viability assay described in Section 6.2 indicated a decrease in 
metabolic activity for the PC-3 cells exposed to BCH-containing liposomes for 48 hours 
when compared to those incubated for the 24 hour increment.  When observed under 
microscope, the cells incubated with BCH for 48 hours had a drastically different 
appearance than those incubated for 24 hours or less.  Cloudiness in the growth medium 
and grainy cell membrane outlines were observed.  Most importantly, clonogenic assays 
for the 48 hour incubation  yielded cell survival percentages that were orders of 
magnitude less than expected.  This observation was also noted, but to a lesser extent, in 
the 36 hour incubation sample.  While cell appearance and growth medium clarity were 
not as significantly different from  normal conditions, clonogenic assays revealed a 
decrease in survivability.  Whether the decrease in proliferative capacity was due to 
boron toxicity, phospholipid toxicity, pH changes within the growth medium due to 
prolonged exposure to the liposome formulation, or another cause is unknown.  Similarly, 
the cause and effect relationship between cell death and boron uptake are also unknown.  
As a future extension of this research, an investigation into whether the boron uptake 
resulted in the loss of proliferative capacity or whether the increase in born uptake was 
mediated by the distressed cell growth environment is of vital importance.  Nonetheless, 
as a result of this set of experiments, future boron uptake experiments were limited to a 
maximum 24 hour incubation time and samples were collected for clonogenic assays 






In addition to the experiments outlined previuosly, representative studies investigating 
cell growth time prior to addition of the liposome formulation, variations in BCH 
concentration within the liposome formulation, and the addition of unhomogenized 
versus homogenized liposome formulation were performed.  There are a seemingly 
endless combination of conditions to study when determining the optimal delivery 
protocol for BCH within a cellular system.  However, when weighing the maximization 
of boron uptake with the desire to maintain cellular function, metabolism, and 





 cell plating density, grown for 48 hours prior to the addition of BCH-
containing liposome formulation  at a concentration of 1.3 g boron/mL of growth 
medium, and incubated for 24 hours. 
 
After identifying this specific boron delivery protocol, the experiment was repeated using 
various cell bank batches of PC-3 cells, separate liposome preparation samples, and both 
HPLC and ICP-MS boron detection  methods to ensure the repeatability of the protocol.  
The six independent measurements resulted in a measured boron uptake of  35.2 + 4.3 g 
boron/g cell.  This uptake is within the range discussed in the Chapter 2 for the boron 
presence in cells targeted for BNCT and provides proof-of-principle that BCH is a viable 







Chapter 7:  Neutron Irradiation and Cell Survival 
 
 
7.1 DNA Damage 
 
 
The biological effects of radiation damage are principally observed as damage to 
deoxyribonucleic acid (DNA).  This damage is in the form of base damage, strand breaks, 
sugar damage, and DNA cross-links, and can be the result of either direct or indirect 
action of radiation.  In direct action, radiation interacts with the target DNA molecule, 
causing ionization or excitation that manifests as biological change.  While direct action 
can be initiated by any form of radiation (x-rays, -rays, charged and uncharged 
particles), it is most often the result of radiation with high-LET.  LET is the amount of 
energy that is transferred to a material per unit length of the radiation track, and is a 
function of the size, charge, and energy of the radiation.  Particles that are large in size 
and carry a charge (i.e. particles) are known as densely ionizing, while low-LET 
radiation (i.e. x-rays) is referred to as sparsely ionizing.  Indirect action, on the other 
hand, occurs as radiation is absorbed by matter (typically water) surrounding the target 
DNA molecule, leading to the formation of free radicals (i.e. hydroxyl radicals).  These 
free radicals then diffuse to the DNA and interact with the target molecule.  Indirect 
action resulting in damage to DNA is predominantly due to hydroxyl radicals.  The G 
value (yield of species per 100 eV) for hydroxyl radical formation in water by  particles, 
such as those released in
10








Figure 7-1.  Diagram illustrating the mechanisms of indirect and direct DNA damage 
from radiation.  Indirect damage results from formation of free radicals surrounding the 
DNA molecule.  Direct damage results from damage imparted by charged particles.[117] 
 
While both densely and sparsely ionizing radiation induce DNA damage, this damage is 
manifested in different ways.  In order to properly relate the fundamental differences in 
DNA damage, it is important to briefly describe the structure of a DNA molecule.  DNA 
is a large molecule consisting of two strands in a double-helical configuration held 
together by hydrogen bonding between the pyrimidine and purine bases.  There are four 
bases and hydrogen bonding occurs between adenine/thymine and guanine/cytosine.  




















Figure 7-2.  Structure of DNA molecule highlighting the hydrogen bonding between the 
base pairs bound to the sugar-phosphate backbones. 
 
Damage most frequently occurs in two ways:  (1) single-strand breaks (SSBs) and (2) 
double-strand breaks (DSBs).  SSBs are readily repaired as the cell utilizes the 
corresponding strand as a template for replacing the damaged section.  Similarly, 
concurrent SSBs that are well separated along the helix are repaired using the opposite 
strand as a template.  However, base damage to strands opposite one another or only 
separated by a few bases often lead to DSBs.  Because the template repair mechanism 
utilized for SSBs is not available, DSBs are a far more critical form of DNA damage and 







Figure 7-3.  Diagrams presenting (A) normal DNA, (B) SSB that can be readily repaired 
using the remaining thymine as a template, (C) SSBs of sufficient separation that repair is 
relatively probable, and (D) DSB in which damage within adjacent base pairs results in 
separation of the chromatin.[118] 
 
The ratio of SSB and DSB formation is a direct result of the radiation LET imposing 
damage to the DNA.  Sparsely ionizing radiation commonly results in SSBs due to the 
release of “spurs” of energy (<100 eV in a 4 nm diameter sphere) along the radiation 
track.  DSBs are dominated by densely ionizing radiation that results in “blobs” of energy 
(100-550 eV in a 7 nm diameter sphere).[118]  Clearly, there is a much larger amount of 
energy released in a local area for densely ionizing radiation.  This results in higher 
concentrations of DNA damage, leading to an increase in the probability of DSBs.  The 
increase in DNA damage, and resulting cell death, as a function of radiation type is 
referred to as relative biologic effectiveness (RBE).  RBE is determined by analyzing the 





standard 250-kV x-ray.  Carrying this concept further, it is understood that low-LET 
radiation will have a smaller RBE when compared to high-LET radiation due to the 
increased probability of DSBs observed in densely ionizing radiation.  RBE as a function 
of LET is depicted in Figure 7-4. 
 
 
Figure 7-4  Relative biologic effectiveness as a function of varying LET radiation.  The 
density of the imparted energy compared to the physical dimensions of the DNA 
molecule provides insight into the formation of SSBs and DSBs.[118] 
 
Mammalian cells are quite efficient at repairing DNA damage, with an average of 10,000 
lesions per day requiring repair due to replication errors, chemical degradation, exposure 
to ionizing radiation, or interactions with reactive oxygen species.[118]  The two main 
mechanisms for repairing the DSBs found in high-LET radiation damage are 
nonhomologous end joining (NHEJ) and homologous recombination repair (HRR).  In 





S/G2 phases of the cell cycle.  In the event that an undamaged chromosome is not 
available, such as in the G1 phase of the cell cycle, NHEJ facilitates ligation of two end 
joints.[118, 119]  This process is prone to errors given the absence of a template and is 
likely the reason DSBs from ionizing radiation are often lethal.[120] 
 
For cells preferentially loaded with BCH, the high-LET  particle and 
7
Li nuclei yielded 
from the thermal neutron capture reaction result in densely ionizing radiation tracks 
traveling within the PC-3 cells.  Section 7.2 of this chapter highlights the enhanced cell 
damage resulting from this high-LET irradiation when compared to the cell proliferative 
capacity response of control cells without boron. 
 
 
7.2 Colony Formation Assays 
 
 
While there are many assays for determining the proliferative capacity of cells in culture, 
the gold standard for quantifying cell reproductive capacity following exposure to 
ionizing radiation remains the colony formation, or clonogenic, assay.[121]  The colony 
formation assay provides a means of detecting the cellular ability to produce a large 
number of progeny following exposure to radiation or other treatment method that can 
cause cell reproductive death due to chromosomal damage, apoptosis, etc.[122]    
 
In order to evaluate the cell reproductive capacity of the PC-3 cells following irradiation 
with thermal neutrons, a clonogenic assay was performed as follows.  Cells were 





Trypsin-0.53 mM EDTA was added to each flask and incubated for 10 minutes.  The cell 
suspension was neutralized with 4 mL of complete growth medium (F12-K with 10% 
FBS) and pipetted up and down for 20 cycles.  Cell concentration in solution was 
determined from a 10 L sample volume using a hemocytometer.  Cell solutions were 
diluted to the target plating concentrations.  Dilutions were performed in 1:10 and 1:5 
ratios and verified with a hemocytometer to ensure reliable cell concentrations in the 
diluted samples.  After accounting for plating efficiency, cells were plated in T-25, T-75, 
and T-150 flasks with a target number of surviving colonies of approximately 50, 150, 
and 300, respectively.  Complete growth medium was added to each flask and placed in 
an incubator for 10 days.  At the completion of the 10-day growth period, growth 
medium was aspirated from the flasks and the cells were washed twice with DPBS.  The 
cells were then preconditioned for fixation with 5 mL/25 cm
2
 of 1:1 DPBS:methanol for 
2 minutes.  The DPBS:methanol was aspirated from the flask and 5 mL/25 cm
2
 of 
methanol was added for 10 minutes for cell fixation.  Following aspiration of the 
methanol, cells were stained with 5 mL/25 cm
2
 crystal violet for 10 minutes.  The crystal 
violet stain solution was aspirated from the cell flask, cells were washed with tap water, 
and rinsed one final time with deionized water.  The cell flasks were dried at room 







Figure 7-5.  PC-3 colonies stained with crystal violet for quantifying the survival fraction 
in a colony forming assay. 
 
7.2.1 Clonogenic Analysis 
 
When determining the efficacy of a bimodal drug-radiation therapy, it is vital to 
understand the impact on proliferative capacity of the individual drug and radiation 
treatments.  Therefore, for each experiment, radiation treatments were performed with 
and without the BCH and parallel clonogenic assays were performed for unirradiated 
cells treated with BCH at identical concentrations and incubation times.  By combining 









 The surviving fraction (SF) is calculated as follows: 
 
    
                                     
                    
   (7-1) 
 
The results of the clonogenic assays are shown in Figure 7-6.  The cell survival 
percentages were corrected for plating efficiency (PE) and normalized to account for the 
proliferative impact of treatment with BCH alone (no radiation).  A thermal neutron 
fluence-dependent decrease in survival of PC-3 cells targeted with BCH was observed 
when compared to the control.  Colony formation assays demonstrated a 20-25% 











.   
 
The shape of the cell survival curve reveals further information regarding the mechanism 
of cell damage within the 
10
B loaded cells.  As discussed previously in Section 7.1, repair 
mechanisms for low and high-LET radiation damage exhibit different behavior within the 
cell.  Briefly, low-LET radiation results in SSBs that are often repaired within the cell.  
Evidence of predominant low-LET damage manifests in a significant “shoulder” for low 
dose irradiations.  As the total dose is increased, repair mechanisms are less effective and 
the cell survival curve slope increases.  For high-LET radiation, however, the initial low 
dose “shoulder” is much less pronounced, if present at all.  The dense distribution of 
energy in high-LET radiation results in a much higher probability of lethal DSBs without 







Figure 7-6.  Cell survival analysis of PC-3 cells with and without BCH and irradiated 



























Chapter 8:  Conclusions and Future Work 
 
8.1  Conclusions 
 
In conclusion, the generation of high-LET  particles and 
7
Li nuclei generated from 
intracellular 
10
B thermal neutron capture reactions within human prostate cancer cells 
preferentially loaded with boron-containing cholesteryl esters is an effective method of 





 resulted in a 20-25% decrease in cell proliferation capacity.  The 
decrease in cell proliferative capacity, as quantified by colony formation assays, is dose-





range.  The densely ionizing radiation emitted from the capture reaction induces DNA 
damage through direct and indirect action.  Direct action from high-LET radiation 
produces double-strand DNA breaks with high probability due to the pattern of energy 
deposited along the ionization tracks.  Indirect action is the result of free radical 
formation and diffusion within the aqueous environment surrounding DNA, causing 
single-strand and double-strand DNA damage.  Although the distinction between direct 
and indirect mechanisms of DNA damage was not specifically evaluated, it is predicted 
that a majority of the lethal double-strand breaks are due to the direct action of the high-
LET particles.  The radiation-chemical yield of hydroxyl radical formation (G (
•
OH) < 
0.5 per 100 eV) from 1.5 MeV  particles in water is relatively low compared to 
hydroxyl radical yields from low-LET radiation (G (
•
OH) > 2.5 per 100 eV).  The low 
hydroxyl radical yield from  particles is due to free radical recombination along the 






Capitalizing on the lack of feedback regulation of low-density lipoprotein (LDL) 
receptors by human prostate cancer PC-3 cells, a cholesteryl ester mimic containing 
carborane was selected as a promising BNCT agent.  Due to the hydrophobicity of the 
BCH compound, it was concluded that encapsulation within the lipid bilayer of DPPC 
and cholesterol-based liposomes was necessary to enhance intracellular delivery.  
Encapsulation in the lipophilic region of the liposomes likely facilitated the transfer of 
BCH into the cholesteryl ester-based core of LDL, resulting in intracellular delivery of 
the boron through receptor-mediated endocytosis.  This drug delivery technique provided 
a means of selectively targeting PC-3 cells by utilizing an inherent biological pathway, 
and without which uptake of BCH into the cancer cells would have been unachievable at 
the quantities required for BNCT.  BCH-containing liposome formulations were prepared 
by the thin film hydration method and subsequently exposed to high-pressure 
homogenization to convert the large multilamellar vesicles (LMV) into small (SUV) and 
intermediate-sized unilamellar vesicles (IUV).  Dynamic light scattering (DLS) size 
analysis of the liposome formulation yielded a mean liposome diameter of 111.5 nm with 
a 0.113 relative variance using the non-negatively constrained least squares (NNLS) 
algorithm for multimodal size distribution analysis.  Conversion of the LMV to 
SUV/IUV enhances the transfer of BCH cholesteryl ester compounds to LDL within the 
cell media. 
 
The cytotoxic effect of the BCH-containing liposome formulation was analyzed using 





liposome concentration within the cell growth medium were evaluated to ensure cell 
damage to the target population was attributable to the 
10
B thermal neutron capture.  
Active uptake and concentration of neutral red dye into the lysosomes remained 
comparable to the control study for all conditions except the 24 hour incubation with 2x 
liposome concentration in the cell growth medium, where a statistically significant 
decrease to 75% of the control was measured.  Metabolic activity related to bioreduction 
was evaluated based on the MTS assay.  Addition of BCH-containing liposomes to the 
PC-3 cells resulted in increased metabolic activity over a 24 hour time period in a 
concentration-dependent manner.  After 48 hours, however, metabolic activity returned to 
equal (1x) or decreased (2x) values compared to the control.  A disruption in bioreduction 
is an indication of the onset of toxicity effects within the PC-3 cells for the prolonged 
drug exposure.  The integrity of the cell membrane following incubation with the 
liposomes was evaluated via the LDH assay.  In each sample, no significant increase in 
membrane leakage of cytosolic material was observed.  In a final method to evaluate the 
cytotoxic effect of BCH, colony formation assays were performed to quantify the long 
term clonogenic capacity of the cells.  For samples exposed to the BCH-containing 
liposomes in excess of 24 hours, a reduction in proliferation of a few orders of magnitude 
was observed.  The results of a range of assays to detect changes in cell behavior, 
including transport mechanisms, metabolic activity, structural integrity, and clonogenic 
capacity, were used to evaluate the drug delivery conditions for boron delivery to the PC-
3 cells.  Based on the data collected, a 24 hour incubation time with 1x liposome 






Cellular uptake of boron by the PC-3 cells was quantified by high-performance liquid 
chromatography (HPLC) and inductively coupled plasma-mass spectrometry (ICP-MS).  
HPLC provides direct measurement of the intact BCH compound, while the ICP-MS 
methodology measures the presence of 
10
B within the sample.  Drug delivery conditions 
selected to minimize cytotoxic effects of the liposome formulation, as characterized with 
the assays listed above, resulted in a boron uptake of 35.2 + 4.3 g/g cell.  This value 
exceeds the recommended therapeutic specification of ~20 g/g cell for successful BNCT 
treatment. 
 
Because the thermal neutron capture cross section of 
10
B is dependent on the energy of 
the incident neutron, it was determined that direct measurement and computational 
modeling of the neutron spectrum within the thermal column experimental facility was 
required to adequately evaluate the efficacy of 
10
B capture in BNCT treatment. 
Measurements of the neutron spectrum were achieved through a combination of 
experimental measurements, deconvolution of detector responses, and MCNP modeling 
of the MUTR core and surrounding facilities.  Experimental neutron measurements were 
accomplished by passive neutron detection combined with resonance absorptions, 
threshold reactions, and moderate and capture techniques.  The increase in detector 
responses afforded by the diverse range of neutron detection methods resulted in high 
spectral resolution of the thermal neutron energy range.  Deconvolution of the detector 
responses was performed based on the maximum entropy principle encoded into 
“MAXED” with a RATE-generated starting spectrum and MCNP5 response matrices.  





MUTR for benchmarking and verification.  The neutron fluence rate within the entire 
energy spectrum (10
-9 
– 16 MeV) was within 5% when comparing the experimental 
measurements with the MCNP/X computed model.  Within the < 3 eV neutron energy 
range, results of the two methods were also within 5%.  The greatest variation (17%) 




MeV energy range can 
be attributed to a spectrum shift resulting from variations in the final sample chamber 
configuration compared to the modeled chamber, and temperature modeling within the 
thermal column.  The presence of a hydrogenous sample chamber surrounding the 
neutron detectors in the experimental measurement contributed to further thermalization 
of the neutron field that was not accounted for in the computer model.  In addition, 
neutron scattering within the thermal column experimental facility is largely dependent 
on the molecular motion of hydrogen, whereby small discrepancies in temperature can 
shift the Gaussian distribution of thermal neutron energies.  These sources of error are 
present when evaluating narrow energy bands, however, integral neutron fluences over 
larger energy regions decrease this uncertainty.  Accounting for fluctuations in nuclear 
reactor power with real-time monitoring, anisotropy in the neutron beam, fluence rate 
uniformity across the sample chamber plane, and starting spectrum bias in deconvolution 
were integral in attaining accurate unfolding of the neutron spectrum. The thermal 
neutron fluence rate at 250 kW reactor power within the sample chamber was determined 




/s, with the < 3 eV thermal neutron energy region representing 
94.6% of the total neutron field.   Thermal neutron moderation within the thermal column 
facilitating 
10
B thermal neutron capture resulted in a factor of five dose enhancement, 







B).  The gamma ray dose rate of 0.94 + 0.6 cGy/min was measured within the 
thermal column experimental facility at 250 kW using an ionization chamber.  This 
gamma ray dose rate is within the recommended specification of 1 Gy/hr for BNCT 
facilities.   
 
8.2 Future Work 
 
The development of a nuclear reactor experimental facility and subsequent analysis of a 
boron-containing agent for BNCT leads to further research directions.  Several questions 
remain regarding optimization of thermal neutron irradiation and intracellular delivery of 
BCH. 
 
Thermal neutron irradiation within the MUTR thermal column is capable of providing 
sufficient thermal neutron fluence rates for the evaluation of the BCH compound; 
however, enhancement of the fluence rate is possible through modification of the graphite 
assembly.  The current configuration allows for customized graphite stringer 
arrangements within the moderator array.  Through computer modeling and experimental 
measurements, location of the sample chamber in closer proximity to the reactor core in 
combination with various moderator/shielding materials could increase the thermal 
fluence rate while maintaining a low gamma ray and fast neutron contribution to the 
delivered dose.  In addition to increasing the thermal fluence rate, the epithermal neutron 
ratio could also be increased.  This would allow a variety of sample chamber caps to be 
installed, enhancing environmental control within the chamber while providing sufficient 





500 kW or 1 MW would also enhance research capabilities within the thermal column of 
the MUTR, as neutron fluence is directly proportional to thermal power. 
 
Future evaluation of the BCH compound for delivery to PC-3 cells is also important.  By 
investigating the transfer of BCH cholesteryl ester mimics from liposomes to LDL, it is 
possible that increased 
10
B uptake can be achieved.  Variations in liposome size and BCH 
concentration within the lipid bilayers should be studied to determine optimal transfer 
conditions.  In addition, further understanding of the cytotoxic mechanisms related to 
boron delivery to PC-3 cells would be a valuable contribution to the BNCT drug delivery 
field of research.  The mechanisms related to observed metabolic stimulation following 
exposure to BCH-containing liposomes and significant reduction in long-term 
proliferative capacity for exposure times in excess of 24 hours should be investigated 
further.   
 
And finally, continuing this research to include the BCH-related compounds 
incorporating fatty acid chains bound to the cholesteryl ester would provide a more 
thorough understanding of the potential for targeted delivery of boron within cancer cells 
systems.  Once proof-of-principle has been established, the use of 
10
B-enriched carborane 
with the BCH family of cholesteryl esters for treatment of cancer systems provides an 
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The purpose of this proposal is to provide a detailed procedure on how to remove the 
access plug from the thermal column of the Maryland University Training Reactor. 
Removing the access plug will allow personnel to place experiments near or in the 
thermal column in order to obtain thermal neutrons.  
 
 
PRECAUTIONS AND REQUIREMENTS 
 
Removing the access plug is classified as a Special Experiment. Therefore this proposal 
requires the approval of the Reactor Safety Committee and the Reactor Director. This 
proposal must also comply with the guidelines set by 10 CFR 50.59. 
 
The access plug to the thermal column has never been removed, so the dose rate that one 
may receive from activated particles in the thermal column is unknown. 
 
The access plug must be removed in intervals, and radiation readings must be taken at 
each interval.  These readings will be recorded and analyzed to predict trends before the 






The withdrawal intervals should be approximately 1 inch. By keeping the intervals very 
small, the access plug can be easily inserted if radiation levels reach an unacceptable 
level.   
 
If at any time during the withdrawal process the radiation exceeds 100 mrem/hr, removal 
of the access plug will cease and exposure times evaluated with the assistance of the 
Radiation Safety Officer [76]. 
 
According to the technical drawings, the weight of the access plug is 800 lb. Therefore, a 
manually operated lever hoist rated at 2000 lbs will be used to remove the plug. This 
provides a safety factor of 2.5. 
 
The reactor must be secured and shutdown at least 5 days prior to the experiment and 
during the withdrawal and insertion of the shielding plug and/or graphite stringers. 
 
The calibration of all radiation monitoring devices utilized in the removal process shall 
be verified within 24 hours of plug removal. 
 
 
REQUIRED MATERIALS AND PREPARATIONS  
 
Chain to mark off high radiation area 





Leather gloves for personnel involved in removing the access plug 
Safety goggles for all personal involved in the removal or replacement 
Neutron detectors and gamma/beta detectors to monitor radiation near the face of the 
access plug. 
Table rated at 2000 lbs. to support the access plug once it has been removed. What is 
significant about this cart is that the surface consists of casters which will enable workers 
to easily guide the access plug back into the thermal column. The sides of the cart will 
contain lips to ensure that the plug does not fall off the cart.  
Full body protective suit for all personnel entering the confines of room 1308 while the 
insert is either in transit or removed from the fully inserted position. 






Review the control room log book to ensure that the reactor has been shutdown for at 
least 5 days. 
 
Mark off the area with tape. There should only be 3 personnel allowed in the radiation 
area during the removal of the access plug. One will remove the plug, one will monitor 





The entire plug will be enclosed by means of a modified glove bag or equivalent barrier 
to minimize the effects of disturbing the dust and or contaminants that may have 
accumulated since the plug was last removed.  Radiation levels will be monitored by a 
RSO representative who shall maintain air monitoring within the glove bag and will 
evaluate the readings every quarter hour.  This information will be recorded and 
maintained with the final report for this project. 
 
Set up a neutron detector and a gamma/beta detector near the face of the access plug. 
Take neutron and gamma/beta readings at this time and record the readings.  
 
Attach the lever hoist to the hook on the face of the south wall. Attach the other end of 
the lever hoist to the hook on the access plug. Make sure that you have attached the lever 
hoist to the access plug and not to the thermal column plug. 
 
Position the cart so that the access plug will be pulled onto the top of the cart. 
 
All members in the radiation area must don leather gloves, safety goggles, and be 
equipped with a self-reading dosimeter which will be evaluated and recorded every 15 
minutes to monitor radiation exposure. 
 
Using the lever hoist, slowly remove the plug approximately 1 inch and stop. Take 






NOTE: If at any time the radiation readings exceed 100 mrem/hr, immediately cease 
removal of the plug and notify the RSO representative of the readings so that exposure 
times may be calculated. 
 
Repeat Step 4.7 until the access plug is completely removed and is safely secured on the 
cart.  Photograph and perform radiation wipe test on all interior faces with assistance 
from the RSO.  
 
Look into the void where the access plug normally occupies and observe the face of the 
thermal column. There should be 4 exposed graphite stringers. Record and photograph 
their condition and report any damage or abnormalities. 
 
RECOVERY AND REPLACEMENT OF PLUG 
 
The plug shall be fully inserted before the reactor is removed from a secured condition as 
defined by the Technical Specifications. 
 
No operations of the reactor shall resume until such time that the radiation levels are 
demonstrated to be that of pre-removal levels.  A review of these levels shall be 
forwarded to the Reactor Director who shall review the results and provide 
recommendations as to whether the Chair of the Reactor Safety Committee should 








The removal of the thermal column does not require a License Amendment Request 
(LAR) as allowed under 10CFR50.59 for the following reasons: 
This removal of the plug does not require a modification of the Technical Specifications. 
(10CFR50.59(c)(1)(i) 





In the event that the radiation levels exceed the limits set forth previously, the 
measurement process will cease immediately.  At this point the plug will be inserted fully 
into the core.  In the event that the insertion may not be accomplished either due to 
binding of the plug or failure of components of the withdrawal/insertion system, the plug 
shall be inserted manually.  This manual insertion shall be accomplished by use of eight 
foot long rigid bar stretched across the face of the plug and inserted by using two staff 
members on each end that will physically push the plug into place.  The plug shall remain 
in this position until such time that the Reactor Director is satisfied that the failure mode 
has been corrected.  The Reactor Director shall produce a written plan that describes the 
failure mode and measures taken to mitigate the possibility of a subsequent failure. 
In the event that the plug shall shift or fall resulting in physical injury to personnel, 





system.  This radio shall be kept within 2 meters of the thermal column at all times when 
the insert is either in motion or any other condition where the plug is not fully inserted 
into the reactor vessel.  In the event that the plug is damaged, the reactor shall be placed 
into a shutdown and secured condition.  The Reactor Director shall take possession of the 
console key and a sign placed upon the console indicating that operations are suspended 
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The purpose of this proposal is to provide a detailed procedure on how to measure the 
neutron and gamma-ray dose rates using ion chambers at various locations within the 
thermal column of the Maryland University Training Reactor.  Measuring the dose rates 
will provide valuable information about the types of experiments that can be performed 
within the thermal column, especially in the field of nuclear medicine.  
 
 
PRECAUTIONS AND REQUIREMENTS 
 
Removing the access plug is classified as a Special Experiment. Therefore this proposal 
requires the approval of the Reactor Safety Committee and the Reactor Director. This 
proposal must also comply with the guidelines set by 10 CFR 50.59. 
 
The Maryland University Training Reactor has never been run at power with the thermal 
column open, so the exposure of individuals working in the reactor building while 
measuring dose rates within the thermal column are unknown. 
 
The dose rates must be measured while running at various power levels.  These readings 







If at any time during the radiation measurement process the radiation exceeds 100 
mrem/hr outside of the thermal column, a high radiation area will be established and 
marked allowing positive control over individual access to the area in accordance with 10 
CFR 20.1601. 
 
Neutron detectors and gamma/beta detectors will be used to monitor the radiation levels 
at the face of the thermal column, as well as in the area where the ion chamber readings 
are being recorded. 
 
In order to house the ion chambers at a stable location within the thermal column, an 
aluminum casing will be designed and fabricated so that no personnel is required to be 
near the opening of the thermal column when the reactor is operating.   
 
After placement of the ion chambers in the thermal column, the access plug will be 
partially inserted into the thermal column to shield as much radiation as possible.  Care 
will be taken to ensure that the integrity of the ion chambers and corresponding wires are 
not compromised by the insertion of the access plug. 
 
Stay times will be calculated before removing the ion chamber housing, made of 






The calibration of all radiation monitoring devices utilized in the removal process shall 
be verified within 24 hours of dose rate measurements. 
 
Communication between the personnel on the ground floor taking dose rate 
measurements and reactor operator in the console will be through radio. 
 
 
REQUIRED MATERIALS AND PREPARATIONS  
 
Chain to mark off radiation area. 
Lever Hoist – Columbus McKinnon Model 5318, rated at 3000 lbs or equivalent. 
Neutron detectors and gamma/beta detectors to monitor radiation. (2 each) 
Binoculars for monitoring detectors from South balcony. 
Table rated at 2000 lbs. to support the access plug once it has been removed. The sides of 
the cart will contain lips to ensure that the plug does not fall off the cart.  
Far West Technology Model IC-18, 0.1 cc ion chambers (2) 
Keithley 6514 System Electrometer 
Keithley low noise cable kits (2) 
Canberra 3002 D power supply 
Custom aluminum ion chamber housing 










Connect the cables from the electrometer to the ion chambers and place the ion chambers 
secured in the aluminum housing at the face of the lead bricks within the thermal column 
closest to the core.   
 
Partially insert the access plug into the thermal column without touching the ion 
chambers or the cables. 
 
Set up the neutron and gamma/beta detectors at the thermal column face and on the south 
balcony. 
 
Notify the operator at the console that the ion chambers and access plug are in place and 
direct all personnel to the south balcony.   
 
Increase reactor power and record dose rates from the ion chambers.   
 
Secure the reactor for at least 24 hours prior to second round of measurements. 
 
After 24 hours has passed, remove the access plug and place the ion chambers in the 






Set up the neutron and gamma/beta detectors at the thermal column face and on the south 
balcony. 
 
Notify the operator that the ion chambers are in place and direct all personnel to the south 
balcony. 
 
Increase reactor power and record the dose rates from the ion chambers.   
 
Secure the reactor and wait for at least 24 hours before removing the ion chambers and 




The removal of the thermal column does not require a License Amendment Request 
(LAR) as allowed under 10CFR50.59 for the following reasons: 
This removal of the plug does not require a modification of the technical Specifications. 
(10CFR50.59(c)(1)(i) 









In the event that the radiation levels exceed the limits set forth previously as a high 
radiation area and becomes a very high radiation area, the measurement process will 
cease immediately.  The reactor will be secured and all individuals will evacuate.  Once 
the radiation levels have returned within the limits, personnel will insert the access plug 
into the thermal column.  The Reactor Director will produce a new plan for dose rate 
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The purpose of this proposal is to request approval by the Reactor Safety Committee to 
perform irradiations of biological samples inside the thermal column of the MUTR using 
the protocol described in the following sections of this document.  Previously, an 
environmental control thermal column access plug was designed and fabricated to house 
samples within the thermal column for exposure to thermal neutrons from the MUTR.  
The neutron spectrum and gamma dose rates have been measured and can now be used to 
develop radiation protocols for the in vitro irradiation of biological samples.  The goal of 
this set of experiments is to determine the efficacy of a boron-containing cholesteryl ester 
mimic as an agent for Boron Neutron Capture Therapy (BNCT) of human prostate 
cancer.   
 
MATERIALS TO BE IRRADIATED 
 
The irradiated samples will include T-25 polystyrene tissue culture flasks containing 
human prostate cancer PC-3 cells, 5 mL of cell media (90% F12K and 10% fetal bovine 
serum), and 0.2 mL of boron-containing liposomal formulation (contains DL--
dipalmitoylphosphatidylcholine (DPPC), cholesterol, and a boron-containing cholesteryl 
carborane ester compound(BCH)).  The specification sheets for F12K and FBS are 
attached with this proposal.
1,2







PRECAUTIONS AND REQUIREMENTS 
 
Removing the access plug is classified as a Special Experiment. Therefore this 
experiment requires the approval of the Reactor Safety Committee and the Reactor 
Director. This proposal must also comply with the guidelines set by 10 CFR 50.59. 
 
The Maryland University Training Reactor has previously been run at power with the 
thermal column partially open, thus the exposure of individuals working in the reactor 
building while measuring dose rates within the thermal column has been performed and 
is understood.  For the in vitro irradiations, the thermal column access plug will be fully 
inserted into the reactor thermal column during operation, significantly reducing the dose 
rates around the reactor area.   
 
Additionally, the neutron spectrum and gamma dose rates have been measured within the 
thermal column and thermal column access plug using ion chambers and foils.  This 
allows the user to predict activation of experimental material and also provides insight 
into the activation of reactor structure, including the thermal column access plug, 
following exposure to a neutron flux. 
 
Special consideration and planning was considered in the design and fabrication of the 
new thermal column access plug to ensure that adequate shielding is provided for 





new plug is very similar to the existing setup, with a stepped feature approximately half 
way down the plug to  prevent streaming from the reactor core.  The construction of the 
plug consists of ½ inch carbon steel plates.  Additionally, all pipe fittings are specially 
ordered carbon steel.  Caution was taken to eliminate stainless steel components from the 
plug to limit the 
60
Co created from thermal neutron irradiation of the plug components.  
The piping which delivers the water and gas to the sample chamber is copper.  In order to 
account for creation of 
16
N within the water and air channels, 50 feet of copper tubing 
was coiled on the outlet paths to increase the time required to exit the plug shielding.  
Given the half-life of 
16
N as 7 seconds, this will provide adequate decay of the isotope 
within the plug.  Once the internal components were tested, the access plug was 
backfilled with concrete for shielding.  While pouring the concrete, care was taken to mix 
thoroughly to avoid air gaps.  As a final measure, the length of the plug was extended 2 
inches to increase the shielding planar to the sample chamber.  During this particular set 
of experiments, there will be no gas or water flow through the thermal column plug. 
 
If at any time during the sample irradiation the radiation level exceeds 100 mrem/hr 
outside of the thermal column, the operation will be paused and a high radiation area will 
be established and marked, allowing positive control over individual access to the area in 
accordance with 10 CFR 20.1601.  The establishment of a high radiation area, if 






Neutron detectors and gamma/beta detectors will be used to monitor the radiation levels 
at the face of the thermal column while loading, irradiating, and unloading samples in the 
thermal column. 
 
The materials beings used in this set of experiments have been reviewed and no 
degradation that could cause an unanticipated increase to the hazards of experimental 
personnel is expected under the required operating conditions.  Polystyrene tissue culture 
flasks have previously been exposed to significantly higher mixed neutron/gamma fields 
with no signs of physical degradation or long-lived activation.  The break-down of 
styrene into its degradation products is not expected to result in a significant chemical-
based risk to personnel handling the irradiated materials. 
 
Previous experience with irradiated cell cultures has shown that there is very little 
activation of the cells or cell media.  The polystyrene flasks tend to become slightly 
activated.  It is estimated that a majority of the activation comes from the dyes used in the 
caps for the flasks and plasticizers.  Activation products from previous irradiations of 
these flasks at AFRRI include Na-22, Na-24, Zn-96m, As-76 and Ru-106.  The presence 
of Na-24 can be drastically reduced by handling the flasks with gloves rather than bare 
hands.  Attached to this proposal is a gamma spectroscopy analysis of a Corning tissue 









Communication between the personnel and reactor operator in the console will be 
through radio. 
 
Radiation safety personnel will survey the samples after they are removed from the 
sample holder prior to release to the cell laboratory.   
 
The liquid cell media that has been irradiated will be transferred to a bottle with a cap in 
the biological safety cabinet (BSC).  This bottle will be labeled as radioactive material 
and be placed on an absorbing pad to ensure any spills are contained.  There are two ways 
that the liquid can be treated from this point:  1) The bottles can be surveyed and if they 
are below background they can be treated as normal biological waste (neutralized with 
bleach and poured down the drain) or 2) Plaster of Paris can be added to the liquid to 
convert it to a solid. 
 
Solid samples (cell culture flasks) will be disposed of into a radioactive waste 
container.  The radioactive waste bags will be held in storage until they are at background 
levels with no removable contamination.  At that point they can be autoclaved prior to 
disposal with other biological waste.  On the other hand, the samples could also be 
transferred to a waste disposal contractor.  Final determinations on the method of waste 
storage and removal will be made by Radiation Safety. 
 
 






Plastic chain, posts, and appropriate signage to mark off radiation area. 
Lever Hoist – Columbus McKinnon Model 5318, rated at 3000 lbs or equivalent. 
Neutron detectors and gamma/beta detectors to monitor radiation. 
Table rated at 2000 lbs. to support the access plug once it has been removed.  
Radiation monitoring as recommended by the Radiation Safety Officer or their appointed 
representative. 







In vitro cell culture samples will be grown in T-25 Corning polystyrene tissue culture 
flasks prior to irradiation in the thermal column.  The irradiated material will include a T-
25 polystyrene tissue culture flask, 5 mL of cell media (90% F12K and 10% fetal bovine 
serum), 0.2 mL liposomal formulation (containing BCH, DPPC, and cholesterol), and 
human prostate cells PC-3. 
Cells will be transported from the tissue culture laboratory and washed prior to securing 
the samples in the thermal column.  Washing the flasks prior to irradiation will minimize 
the contaminants that can be activated by the neutron flux during the irradiation.  Flasks 





Flasks will be placed in the sample chamber of the thermal column access plug and the 
plug will be fully inserted into the thermal column. 
Samples will be irradiated in the thermal column with the reactor at 250 kW for up to 20 
minutes. 
The reactor will be scrammed and the end of the desired irradiation time and allowed to 
decay for 10 minutes. 
While monitoring the radiation levels with neutron and gamma detectors, the thermal 
column access plug will be removed and the samples will be retrieved from the plug. 
The samples will be surveyed with radiation monitoring instruments to ensure that they 
can safely be transferred to the tissue culture laboratory for analysis.  In addition, the 
samples will be swiped to test for removable contamination. 
Upon completion of the experiment, the standard thermal column access plug will be 
fully inserted into the thermal column after the reactor is in a shutdown condition. 
 
Post-irradiation Cell Colony Forming Assay Procedure: 
 
Transfer cells to the cell culture laboratory. 
Remove cell flask from the transfer container and place in the biological safety cabinet 
(BSC). 
Remove irradiated cell flask cap and replace with new cap.  Dispose of irradiated cap in 
dry Rad Waste Bin. 
Discard irradiated media into liquid Rad Waste Container located in the BSC.  Liquid 





Add 0.5 mL of trypsin-EDTA (25%) to the cell flask and incubate for 10 min. 
Transfer cell flask to BSC and add 5 mL of medium to the flask.  Using a pipette, mix the 
solution thoroughly. 
Transfer desired volume of cell solution to new cell flasks, add 5 mL of media, and 
incubate for 10-14 days. 
Dispose of irradiated flask in the dry Rad Waste Bin. 
After incubation for 10-14 days, transfer cell flask to BSC. 
Discard media into liquid Rad Waste Container. 
Rinse the cells with 5 mL PBS and discard PBS into liquid Rad Waste Container. 
Add 10 mL of 50:50 methanol:PBS solution to the cells and rinse.  Discard solution in 
liquid Rad Waste Container. 
Add 5 mL methanol to the flask and fix for 10 min. 
Discard methanol in liquid Rad Waste Container. 
Add 3 mL crystal violet to the flask and stain for 10 min. 
Discard crystal violet into liquid Rad Waste Container. 






 The removal of the thermal column does not require a License Amendment 





 This removal of the plug does not require a modification of the technical 
Specifications. (10CFR50.59(c)(1)(i) 
 The proposed experiment has been evaluated and does not meet the criteria set 
forth in 10CFR50.59(c)(2) 
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List of Abbreviations 
ABNS:  accelerator based neutron source 
ANOVA:  analysis of variance 
BCH:  cholesteryl 1,12-dicarba-closo-dodecaboranel-carboxylate 
BNCT:  boron neutron capture therapy 
BNL:  Brookhaven National Laboratory 
BPA:  4-dihydroxyborylphenyl-alanine 
BSE:  Bayesian statistical estimator 
BSH:  borocaptate sodium Na2[closo-B12H11SH] 
CHOL:  cholesterol 
DC:  direct current 
DLS:  dynamic light scattering 
DNA:  deoxyribonucleic acid 
DPBS:  Dulbecco’s Phosphate Buffered Saline 
DPPC:  1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DSB:  double-strand break 
eV:  electron volt 
FDA:  Food and Drug Administration 
FWHM:  full width at half maximum 
GB-10:  polyhedral borane dianion [closo-B10H10]
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GBM:  glioblastoma multiforme 
HPGe:  high-purity germanium 





HRR:  homologous recombination repair 
ICP-MS:  inductively couple plasma mass spectrometry 
IUV:  intermediate-sized unilamellar vesicle 
LDH:  lactate dehydrogenase 
LDL:  low-density lipoprotein 
LET:  linear energy transfer 
LMV:  large multilamellar vesicle 
LoB:  limit of blank 
LoD:  limit of detection 
LoQ:  limit of quantitation 
MCMC:   Monte Carlo Markov Chain 
MCNP:  Monte Carlo N-Particle 
MDS:  multimodal size distribution 
MITR:  Massachusetts Institute of Technology Reactor 
MUTR:  Maryland University Training Reactor 
MTS:  3-(4,5-dimethylthaizol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
NADH:  nicotinamide adenine dinucleotide dehydrogenase 
NADPH:  nicotinamide adenine dinucleotide phosphate 
NARP:  non-aqueous reverse phase 
NHEJ:  nonhomologous end joining 
NIST:  National Institute of Standards and Technology 





PC-3:  human prostate cancer cell line 
PC:  phosphatidylcholine 
PCS:  photon correlation spectroscopy 
PDT:  population doubling time 
PE:  plating efficiency 
PMMA:  poly(methyl methacrylate) 
QELS:  quasi-elastic light scattering 
RBE:  relative biologic effectiveness 
RF:  radiofrequency 
RSD:  relative standard deviation 
SF:  surviving fraction 
SSB:  single-strand break 
SUV:  small unilamellar vesicle 
TC:  thermal column 
TLD:  thermal luminescent detector 
TRIGA:  Test, Research, Isotope production General Atomic 
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